R¢gistrnd number: 082397 Charity number: 1149638 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlted by Guarantee) TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 Iillwillll AC81N5KX*
178
COMPANIES HOUSE
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Conwny Limtsd by Guarantee) CONTENTS Page Refee and Administrati D•tails of the Company. its Trust•e5 and Advisers Truste•s' Rtport 2-16 Trustees. Respon$ibllttl•s Statèmtnt Independent Auditors. Report on the Finanelal Statements 18-21 Statement of Fin•n¢i41 ktivi¢ies 22 Balance Sheet 23 Statefflent of Cash Flows 24 Notes to the Flnan¢l•l Statements 25-44
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES
Company Linatsd by Guarant*l
REFERENCE ANO ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND AOVISERS
FOR THE YEAR ENDEO 31 DECEMBER 3J22
Trusttts
V Paèes, secret Genèral {appoinled 1 January 2017, t&mi èndèd 31 December
20221
P Laidkr. Chaii Ex•cutNe Corrwnittee lappointed 1 January 2020)
F Michelangeli, T¥Surer lappointed 1 January 20171
F G Salin, Chair, Education Commrttee lapwnted l Januwy 20191
l Diaz Moreno, Chair. W0"ng Group on thè Carèèrs of Young Scientists
(appointed 1 January 20181
C Arraiano. Chair. Working Group on Women in Science {appointed 1 January
2014, tÈrm ended 31 December 20221
B Vértessy, Chair, Advance
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) TRUSTEes' REPORT FOR THE YEAR ENOEO 31 DECEMBER 2022 The Trustees present their annual report logelher wth the audrted ffinancial statement5 Qf thg Corrpany for the year 1 January 20r2 to 31 Dtetrrkner 2022. The Annual Report SèNèS the purposès of both a TrustèÈs' report and a directors. report under company law. The Trustees confirm that the Annual Report and financial statements of the charrtat4e Company compty with the currenl statutory requirernents, the requirements of the charitable companys goveming document and the provisKJns of tht Statèment of Recommended Practi¢e ISORPI applKable to charrt'es prepanng their accounts In accordance wrth the Financial Reporting Standard appluble in the UK and Republic of Ireland {FRs12) lelfectNe 1 January 20191. Sine8 th& Company qualth as uThJer sectK)n 382 of the Coryanps Act 20C6, thg ratogi¢ Rgport requiréd of mèdium and large companies uTrJer th• Cornpanie5 Ad 20C6 (Strategic R•port and Directors. Report) Regulabons 2013 has been omrtted. STRUCTURE. GOVERNANCE AND MANAGEMENT Con$titution FEBS is reglstered as a charty lie9tstered chawty number 114>338}. and is a company limrted by guarantee Iregi51ered company number 08239)971. The Memorandum and Artic$ of Assoc¢atson by which FE8S was governed in 2022 can be found here.. htS.'1.rebs.¢rfftC0ntenUuplQadsl2022lo8ffEBS_- Mernofandum and Articles of_ASsociatn.pdf. Organisation and membership FEBS was founded on 1st January 1964 and is a Federab"on of biochemisty and molecular b¢ology Societ5. In 2022, its Constrtuent socieb.es spanned 39 countrie5 in Europe and neghbouring regions and included 35 Member So¢ielEs and 4 Associate Ilember Socties. The Constrtuent Sockn"es of the Federation in 2022 are 9iven in Appenth'x l. and theif rymb•rSh nurnbers fft APndiX 2 It¢)laling 25.836 indwidual members in 20221. 12 societies - Russia and Belarus - had their menknrship of FEBS suspended follomny a Counul vote in 2022 and they currently remain suspended.) FEBS is govemed by a Council composed of one degate from each of the Con5b"luenl Societies as well as the member5 01 the ExeoJtwe Committee. FEBS Council meets once a year al the annual FEBS Congress. Th¢ Council elects members ol the FEBS ExèculNe Commrttee for three-year term5 (except the Chair and Vice- Ch¥ir posr(ionsl. as well as ordinary mèmbets ofthe FE8S Commrttees and Working Group5 (delegated specific areas of FEBS wofkl for four-ar terms, in a secret ballot. The v-ChaIr of the Execulwe Committee, who after one year becomes Chair. is app)inted by the Swety hostsng the annual Congress and Council Meetsng in the wevious year. Subject to the Couneil, the adThMnislrabon tsf the Ftderation is vested in the FEBS ExecutNe Committee (the 'FE8S Offi"cers'l. The Exe¢ub"ve Commrttee consists of the Chairperson. the Vice£hairpèrson, the FEBS Sectary General. the FEBS Tièasurer, the FE8S Congress Counselh)r, and the FEBS Committee and Wo¥king Cioup Chairp8r50ns. Wrth the eXceptn ol co-OPte(J ActiThJ Chairpetsons le.g. following resignations prr to Council eleciK)nsl, FEBS Olficer5 are the FEBS ¢hanty Trustees and company DireLttors respon$ible for the actions ol FEBS. The narnes of the membèrs of the Execukn"vè Comrruttee and the narnes of members ol other Committeès and WoTking Groups in 2022. together with dates of app(Mntrnents and 9eographKal distribution, are set out in Appendix 3. The FEBS Trusteesnirectors are distingurshed srAentsts and Iwth the exception ol the Executwe Committee Vicè Chair and Chair. as explained above) elected by FEBS Counul from norninations put forward by FEBS Constrtuent Sociètiès. Before formal appM)intment, nthY elected TrUsteeSlreCtors sign the Chanty Commission's 'Declaration of eligibilty for appointed Trustees, and are referred to the Charity Commisslon's gUance the ro of Trustse$ a$ well as Companies House Inlormath?n on Directorlsecretary r&es Page 2
TIIE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantttl TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDEO 31 DECEMBER 2022 OWECTIVES ANO ACTlVtnES Oblectlvés The obieetwes of FEBS are to ¢ontribule to and promote the èdwdn¢ement of rese8r¢h and edueth.oft for the public benefft in the sciences of biochemistry, biology and rek8te%Y disciplines (but only In 50 far as such related dtsciplinès arè ancillary to the main obiectl, by all surtablt means and In partvIar by. holding and arranging congresses, training and educalional courses on malters connected with "ochemislry and molecular biology and related dFsciplines. faciif(ating and supporting the exchaNJe of scientific information befvrten bichemists, mkcular biobgists and scienb.sts working in reL8ted disaplines generalty and èspeaally in Europe and other eountries of Constrtuenl Souetses facilrtating and supporting the training of young scientists in research. in the form of lellowships,. and organisin9 the editing and publication of scnb'fic searCh and educatKJnal material in biochemistry and molecular biokJ9y and related disciplines. Actlvftles The followng paragraphs and thèir assoc43ted append5 ouuirtè aetivthes in X)22 frorn the diffefent Committees and Working Groups of FEBS. Exten5we inlormats.on on FEBS woth is also available on the FEBS website at wM.lebs.org. and hvJhlvJhts appeared in the sue of FEBS News (pdf magazine) in 2022. vhw4.febs.orgln¢w511ebs-newsllnwgazeI. Scièntlffie publrcations FEBS owns lour purna15 for the publication of re5eafch papers. Teview5 and discussM in the molecular lrfe s¢i?n¢¢5." The FEBS Journal. FE8S Letters. Molecular Oncology and FEBS Open Bio. They are published on behaW ol FEBS by Wiley and aim to PrOde highqualty peer rewew. fa51 publicatson, and a variety ol enhane•d fratures for both aulhors and readers. The joumals prowde n$t ofthe income to fvnd FEBS. other a¢lNities. The Pub1rcalio Cornirtlee oversees the operttion and devek)pffÈnt of FE8S' Journals and in 20L was under the chairmanship of Johannes Buchner. Al four Joumals are intematia1IY recognised to be ol high qualty as detsiled below. The four iouma15 are fully digital and can be reached through the FE8S Press platrom {W.1tbsPre$s.cOrnl. The FEBS Press ioumaLs have errt)raced changing publBhing practices and offer simple submission in any formal and a smooth publieation process, with peer review managed by editorial board members who are exp•rts in the field. Thorough ethics and research integrty checks are run by our èxperieneèd èditorial $laff prior trj article publiration. All journals nsm publtsh peT review feports aloft9se research artles. Authors of arti¢le5 rejeetèd by one FEBS Press joumal can choosè to have their manuseript automatically transferred to another All itsumals offer open access options". over 60% oftotal athles published in 2022 were open access {vs 59% in 20211. The FEBS Journal Ivthv.febspumal.orgl publishes high-qualty fvlklength research papers relevant to the M0cular, cellular and biochemical life sciences. The joumal a150 publishes a diverse portfolio of commissioned fronl-half content revwi and edrtorial content. including State-of_the-Art Reviews, Commentaries, Discovery4n- Cgnlext Reviews. Structural Snapshots, Vievfj>oints. Word>of-Advice guides and inteNews with eminent suentists (ln conversth.on Wrth . .). Key metn'cs for 2022." Irr)act Factor 5.4, c(¢eScor8 10.1, Crted Half4ile 8.7 year5, Medrdn time from subnNsSn to first decision after peer rewe•V 38 days. In 2022. the purnal publishèd 470 articles in 24 i55ue5. Authors have the opb.on of publishing their opèn aee&s$. FEBS Letters IvMw.febsletters.orgi, publishes research Teptsrts (both short LetteTr and fun4en9th ath"clesl that significantly impart and advance knedge in the molecular biosciences.. edrtorial spee¢J is a key fealure of the journal. The joumal also publishes a dNerse range of Revie4 (including In a Nutshèll and Per5pectivesl and other fronl-hall content (Comn*ntaries. Stsentsts. Forum). Key melri¢s for 21)22." Irrpact Factor 3.5, CiteSo)re 7.0. Crted HaW-Life 16.8 years. Median b.me for $ubrri$sions to first detysion after peer review 22 days. Page 3
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarant&l TRUSTEES. REPORT ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 In 2022, the joumal published aftides in 24 Sues. Autho have the option of publhshing thèir article open access. olecular Oncology (W¥V.n>)nc0I.orgl publishes hrgfviryiact Tesearch articles in basic, tran$tIonal and clinical cancer research. Thè joumal also publishes corrmtssioned ewS and policy papers discussing enrging concepts in cancer research, caneer diagno&s. prevents.on and care. Key metrics for 2022. Impa factor 6.6. CrteSeoi• 11.8, crted Haif4rfe 4.5 yeats. Median b.me from submission to first dttision after peer rèview 41 days. In 2022, 230 a"¢It$ wefè published in 22 issues. The Joumal is full open acsS. FEBS Open Bio 1m.b$oPnbi0.0rg1, publishes research a"tIeS aeross thè molecular and cellular lrfe sciencès. v4rth the emphasis on lechnical and eth1 qualty rather than subiectNe judgements of significance. Research arbcles on Education in the nleCUlar lrfe sciences are published free of charge. Key metrics for 2022 Irrpad fador 2.6. Crtescore 4.7, Crted Haff4ife 3 7 yea, Medi8n brre from submission to first deeisitsn after peer rewew 33 days. In 2022. 171 articles wère pUished In 12 issues. The journal is full Open Acce5 The FEBS Networ The 'FEBS Neork, plarform. 111 hosts blotype posts offenng insight advice. nthys and comirEntaries for molecular life saentists lunder the Iherre5 Early-carèer Scierrtis( Educator, vWpOInls and Rgsearchl, and 121 supports the devebpment ol an online comrThJnty of scienkn.sts through presentatbon of profiles, and fun¢tsonalrties su¢h as folbwing. commentin9 and open or prwate rooms. It also offers a channel for posts and a prNate room for FE8S Conslrtuent Societies, and hosts vide05 such as interviews and recorded talks. The FEBS Nefvrfoth in 2022 was overseen by the FEBS Netsr WorkJ"ng Group. comprisin9 suentssts delegated from other FEBS Commrttees or elected and chaired by Prof. Xavier Coumoul. Wiley had offered collaboration to develop a FEBS Netmrk in thejournal Publishing AgreeThnI 2012023 and bears the cost ofthe 50fvrfar• provision from the plarform prowder. Zapnrto. The current aims of the FEBS Nebvofk include111 supporting and enhancing the key FEBS activities ofjouma15 and events. as well as Othei FEBS th 5u¢h as education, science & society and fellowships',121 provTding an innovatve offering from FEBS as a new way to support the molecular life sciences community. and131 building more aeeess to ScnttS Interested in FE8S adNities. FEeS Fellowships The report from the 2022 Chairnwn of the FellshIpS Comfftttee, Prof. Alain Krol, provides information on the range of applItIOnS CeNed lor the varwjus categories of FèlhJw5hips. Foll¢Mry the final call for Long-Term Fellowships ILTFI in 2020 (when 77 applicatK)ns were received), 6 new Felk)wships were awarded and were taken up Irom January 2021. the total in post Ojring 2022 wa5 S (Appendi¥ 41 the LTF'S final year In post 1$ 2024 39 éligible Short4•fm Fel¢)w5hip5 ISTFS) applications were recewed in 2022 and 22 wei¢ awarded. These funds enable acb.ve young scientists to work for up to or three mnths in bOratore5 in another FEBS country. In 2021 31 eligiblè SurT¥ner Fdlowship applications were receNed and 10 were awarde¢J to prom15ing Ma51¢rsTrhO students to promde a LaboRtory expernce. 5 Collabor¥tNe Experimentsl Scholarship ICDSI applications were CeNed in 2022. ofwhich 4 wère awarded." the aim of the CDS Is to prowde PhD students and ywng 5cienb.sls from HINARI IResearch4Lifel untrieS wrth travel and daily allowance so that they can carry out experiments which would bè impossitAe in their heme counkn"es. FEBS Excellence Award The first call for this new progrem was wAde in June 21r21. This award is intended for early-career 5¢ienb"5ts who have been estsblished in a salaried capacty in a host insbtution of a FE8S Constrtuènt Society as a Principal Inve5ts'gator IPII for al kast one year. The Award is endowed %Mth a É100,000 grant for 3 years to be used exdusivèly for purchasing consumabl•lequiprrenL In 2022. 16 eligible applications were reeeNed and 10 r+ award611. Ukrainian Short-Term Fellowships IUSTsl'. thest were introduced in sprin9 2022 to help seiènli5ts in or displaced from Ukrainè. They support visits to a host laboiatory for up to 4 months. The decision for acceptance is given rapKlly- usually wrthin 3 week5 01 applying. 10 USTS were awarded in 2022, the majority of them for a 4 monlh period. and OttaSK)nally for 3 months. Page 4
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 Advanced Courses Followng the COVI1>19 pandem, 25 pewnal events took place in 207218 Advanced L•etu(• Courses, 7 joiTht FEBS-EMBO Lectu Coutses, 3 Pracbcal Coursès. 2 PractKal and Lecture Coutsès and 5 Workshops) wth continued EMBO and IUBMB support FEBS Athanced Courses prowde research updates and tèaching from scientific leaders in a pathular field and are pa"culaty valuable for eady-career re5ear¢hers. Interaction gf particrpant$ wrth experts and pe¢ts is ts¢ilrtated through • valhety of sessK)n forTnS. In 2022. grants to course organIse tolalkd approximately E416,C. FurtherrrK)re. Youth Travel Fund IYTF grants, which m 2022 totslled E90.lo. wère gwen to support part"path0n in Athanced Courses to 81 young members of FE8S Conslituent Societies from outsi(Je kne host country 119 YTFS were given in 20211. In addition. 8 IUBM8-tsansLnlinetsI YTFS suppgrted the p4rb"¢ipatson of Students ou151de FEBS aièa. A eollaboratK)n continued befvleen FEBS Athnced Courses Comrruttee and FEBS Letters. which w85 initiated in 2019. Organisers are encouraged lo partKipate In prowding high-quality materkal in a form of a Special Issue or Virtual Issue in order to provide the course organiser5 the OPptunrtY to gain broad vp51bilty of theirwork in well-reputed journal_ Th• 46th FEBS Conge5S The annual FEBS Congress is overseen by the FEBS Congre55 Counsellor (who, in 2022, was Prof. Miguel A. De la Rosal, joinyy with the Secretary General Ivtho. in 2022. was Prof. vaclav Paees. The 46th FEBS Congress was held jointty wrth IUBMB and PABMB, as one singte global event named Thè BCherrStry Global Summit, which took place from 9th to 14th July 2022 in Lisbon, Porbjgal and was hosted by the Portug4Jese Biochemical Society ISPBI. The Congre55 btd was accepted in a vote by the FEBS Council at their meeting in 2018 an¢J was due to be hekl in 2021. but, due to the ongthng Cov119 pandern. the CorMJress was postponed to 2022. Despite the irnpaet of Ihe pandemic. war and rigng infiabon. the Congress attractéd 1.350 participant5 trom 62 countries and the event featured an attractNe scienb.fic prograrn comprising 12 plenary lectures. 36 symposia tOPiC5 arranged under 7 broad thews. 49 inMted symposia speaker5. 6 special sessions in¢ludirrtJ Research and Career Ski115. Science and Society. Edu¢ab"on and Gtrnder Issues and 109 short tslk speakers. The program also featured 902 posters from the submrtted abstracts. Following th• decision taken by FE8S Council lebborated below). FE&S Pded 5pecifjc additional funding support for Ukra5ne sentistS or displacetj from Ukraine vkno afe subnIng abstracts to th• IUBM8-FEB>PABMB Congress. In addition to pravhding a grant forthe organatitin of the Congress. FEBS eontinues to support thè pa.patIOn of young scientists at the èvènt thrwgh Congress bursaries and through rts Young Scntssts' Forum avrdrds lusually 100 partKipants, including the organi&ng corrmrtteel. FE8S pro¥id$s $upport wtth r¢du¢¢d registration fees for FEBS members of Hinari B countries in the FEBS area cal the Sprinzl Schen*. Congress Mana9ement and o•velopt and fvture Congresses Wth the postponed 45th Congress hekj in 2021 and 46th Congress held in 2022, the subsequent FEBS Congresses and Young scienkn.st FOrUn IYSFI [e a150 POStpone(J by one year as follows.. the 47th FEBS Congres5 and we¢ed1j 22nd FEBS YSF wll now be tsking place in July 2023 in Tours, France fo11¢)wng a de¢tsion tsken In March 21)r2. bythe FEBS ExeeLrtNè Coffttnittee and ertdoed by FEBS Council, regarding to cancel the 2tr23 Congress host localion of Moscow, Russia in light of the Ru55ian attacks on Ukraine land suspension of Ihe Russian and 8dawskqn 5o¢ieb"es from FEBS actwrtiesl. the 48th FEBS Congress bid from the ltslk8n SocEty of 8iochetYtsty and Molecular Biology ISlB} was approv and will tsk• place In Mik8n, Itaty in 2024. weceded by the 23rd FE8S YSF. FEes conb.nues lo takè out a cancenation insurance polw for each C0ngre55 and, atthough event insurance cover ha5 changed because ofthe COVID-19 pandem. FE8S conttnues to take out this insUrare policy. as an exanple of FEBS, responsibilities as a chanty to manage risk and effectively delNer rts awns, along with th¢ Page S
THE FEDERAThON OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarant) TRUSTEES. REPORT ICONTINUEOI FOR THE YEAR ENDED 31 DECEMBER 2022 Contracts in place wth the Professional Congress otganiser IPCOI and Host Society. Young Screntists. Forum {YSFI The Chairpèrson of the Working Group on the Careers of Young Scientists, Prof Irene Dlaz-moreno, and an 0¥9an15Ing commrttee of Ung sCnt1$ts organise the YSF. The 21st YSF took place in Conjunction wth IUBMB and PABMB and was hekj in Viffeiro. Portugal 6th - 9th July 20T2 209 applicatnS were receNed from 27 countrie5 and 110 Pfe-and post41octoral young $uenti5ts, In¢luding 11)0 ffom FE8S member societies, representing 33 countries from all over the world Including 26 FEBS membèr society eountries, attended the event. supported by grants from FEBS. IUBMB and PABMB. The progrnm consisted of 4 Keynote Lectures. 9 'YSF Career Speak•rs' across 3 session5 on 'Career Skn"Ils', 'S¢ience frgm another potnt of viev/ and 'F¢llrMships In5KJhts', 3 Seleded Oral COrrffnunat10n sesons. Poster Presentation sessions, as well as social actNrties. YSF participants also attend the COngS$. durin9 the YSF 8ftdge èvent was hehy. In conjunCtn with the decision to hold the 47th FEBS Congress in Tours. France. itwas abo decided lo hokl the 22nd YSF in the same location on 6th to 8th Juty. to be followed by the Congress. This event w8$ orgonised by the Chairperson and an intefnational oigani5ing etsmrryttee ol young sc¢entBts. ENABLE Durin9 the period 2017 to 2021, FEBS and IU8MB were the main sponsors of the ENABLE events. As agreed in 2021, forthe event organisation, FEBS and IU8MB will work with the ENABLE core partner EuTope8n institut8, who will bè appointed fdk)w"ng an open call for bids and who will act as the host and take re5pon51bility for the Symposium each year. There wll also be a Sc*ntffic OrganLsing Committee and Local Organising Commrttee. The agreement runs from 2022 to 2025. The FEWIUBMB-ENABLE Symposium 15 held in Europe in 2022 and 2023. outside Europe in 2024 ar in Europe again in 2025. Travel grant support vrill be provided to young sctentists. The FEB&IUBM&ENA8LE 2022 conference, wrth the tlue "The perfect tandem.. H¢)w teehnology expands the frontiers of biomedicine.. was hosted by the Institute of Biomedicine of Seville IIBISI. in Spain. on 116 November 2022 300 young researchers participated from 31 countii•s wrthin and outside ol the EU. The conference induded a scpèth.fic symposium but also outreach a¢Xwities for the general public and a dedated career day. 10 Sponso 5UPPQrted this intstNe and théir eonIn"butn allowed support tg be gNen for a totsl of 74 travel grants. FEBS 3+ Meètlngs •nd FEBS National Lectures FEBS support5 scientific events of rts Constrtuent SocEties through the FEBS3+ meetings program and the FE8S Natsonal Lecture schemè. ¢verse¢n by the FEBS CCgresS Counsèllor (Prof. Miguel A De la Rosa In 20221. The FEBS3+ meetjngs program provK1è5 lunding lof meetings or9antsèd through collaborations of at least three FEBS Constrtuènt soCtIeS. FEBS approved applicab"on$ lor trtrt) FE8S3+ meetings which took place in 2022. The Machines on G•ne5 meeting h05ted by the Biochemical Socièty IUKI and held in Alicante. Spain in conjunction witti NVBM8 (The Netherfandsl and SE88M Ispainl took place in May 2022. having been postponed from 2021 due to th¢ Cov119 pandemic. This meeting featured 3 plenary speakers, 7 symposia sessions. postèr abstracts and oral tslks wth 47 poster prnter$. The Meeting, hosted by the Estonian Blochemal Souety in conjunctK)n vnth LaBS ILaM"a society) and LBO ILrthuania society), took place In Tallinn, Estonia in June 2022. The meetirrfJ in Estonia included 210 participants190 from Estonia. $8 from Lithuania and 3 8 from Laal. 4 plenary talks arrKJngst So sent[fiC talks including from graduates and PhD-level sci•ntists acfOSS six single and parallel sessions. as well as 77 posters and industry support. FEBS support ¢onsists of 10,000 to the host society for general meeling organi58tion and É10.( to support thé attendanee of young scients.sts from the other partiapating societs"es. In 2022, FEBS supported 10 FEBS National Lecture5. by fvnding the attendance of key speakers from a different FE8S county invrted by a FE8S Constituent Society to their natKJnal meeting through FE8S National Lecture Awards. The len FEBS NatKJnal Leetures were awarded to national society meetings of thè member so¢ietie5 of Croatia. Cypnts. Finland. Frarteè, Italy, L8fvba, Spain, Swedèn, Tunisia and Turkey Ifollowng the postponemènt of many national society m¢$tings duriry the Pande). Page6
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Cowoany Limited by Guaranteel TRUSTEES, REPORT ICONTINUEO FOR THE YEAR eNDEO 31 DECEMBER 2022 Othèr èvents In the Iramework of prorrnting FEBS, journals and FE8S' collaborations wfth related international Organisatn$ of molecular lrfe sciences, FEBS continues to SUPPOfL through sponsorship ol events and travel costs for distinguished speakers to deliver leetuies * annual meetings of leamed soueb.es of bioehemistrylmolecukr b109Y1cell biology in parts of the 1)rfd wrth rapylly devebping contnbub.ons to mobecukr lifè sciences research. Science & SoeS•ty IS&S) The Science and Society CoTh4ttee aclNTtses in the year 2022 included.. the S¢ience and soety Special Session at the IUBMB-FEBS-PABMB Congress in Lisbon, July 2022 on 'RNA SolutK¢ns to genetic an¢Y Infectious diseases, featuring inwted speakers from The Netherlands, Spain and the USA., expanding on the topic ol'Plastscs" revolution, pollution and substrtution. from the 2(r21 FEBS Congress by providing support to constrtuènt SOety Èvènts and activ.•$ on this theme bèing hèld in 2022. Following call for proposaLs, the Science and SoCty Cowffiee prowded grants ofÉ1.SCKI to the Itahan Society of Biochemisty and MOlecur BlogY ISIBI foc their Publ engagernt evenl'l'm in plastsc". if5 not fantast. in November 2022 and to the Spantsh Society fof Biocherristy and Mole¢ular 8iology ISEB8MI for a wdeo project enbtled'How can biop1astics contribute to diminish plastic pollution?. partlp8t1on in 8iomedKal Allnce act'vth'es. Through actNe participab'on in aCtrt$ ol Biond Alliance (General As$¢mblies, Policy officeis, meetings and ts5k forces) the S&S ComThottee contributed in several Suggested documents for the shapirrfj of Eurctpean polKy. including partlP"n9 wrth other organisab'ons to obtain from the EU tht btst research bu¢Jget trth Franwork Program FP9. ParticipaiDn in the FEBS N$tsYork. Education The Education Committee has the rnission of prornb.ng edu¢"on and training of the highest quality in rnolecular life SenCeS in Europe at both vndergraduate and Frtjslgradvate levels. The commrttee's actiwties include.. organising and ftJndin9 edueatlort events, running the EdUtn Ambassadors initiative, supporting the open access journal FE8S Open Bio's section devoted to education and overseeing and contributing to th• Educator Channel on the FEBS Nètsvork. FEBS Education Commrttee also works colboratIVY w rth FE8S AdvancedCourse5 Commttee and FEBS Woiknng Group on the Careers of Young Sciènts"st$_ Thts rs the report from the Chairperson, Prtsf. Fethan Sajin on Education Commrttee actNi(ies planned for 2022. Education Commltte• Meetings: Ihe committee met in-per50n in May 2022 in Izmff, Tortrye (for the first lime since the pandemic) prior to the Ambassadors Meetyng., a second eommrttee meetin9 was hèld in October 2022 in SlbeniK Croatia, pnor lo the EducatKJn Workshop event Four onlin& mthngs ¥Te also held. 6th FEBS Education Ambassadors. Mteting The 6th FE8S Education Arrtjassadors Meeting took place in Izm"r. Tiirkrye on 19 - 20 May 2 022, wrth 28ambassador5 in attendance. Thè meeting program included on day o ne.. 5 short prtssentations from ambassadgrs sharing their educab.on athvr(ies in thè past year, a panel dt5cussion wf(h three talks focused on the history a nd aims of the Ambassadors Inth"ive. the irnportance of education in the mission and vision of FEBS and the roles an¢J fvnth.ons of the Ambassador5 based on the 2021 SWOT analysis vndertaken, followed by group actmkn.es on speof c Ihemes.. and on day two.. a tslk on 'EdueatKJn research and challenges aehiemng publication. foll(wrtd by g roup act¢vilies on specific themes and a final talk on 'a¢¢reditsbon of rnolecular bios(xen¢e degree5 in Europe,. Edueation corrmi Seasonal IN•blna The seasonal webinar series which stsrted in 2ff21 ¢tInued in 222. wrth.. Spnng webinar entitled 'Visual¢ati¢rt in 5rAerKe edalKIn". erne1gg opportunities kn making the invisbble visible Summer webinar entrtlèd'How to SUPPOrt sustsinable supervision of doctoral resear¢hers'; Autumn webinar enbued 'Devebpment of a tea¢hing TrdUle lor PhD (andidates." and Winter webinar entrtled 'Asse55ment 101 beyont1 in Lrfe s¢ènCes edtn.. Page 7
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarantee) TRUSTEES. REPORT {CONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 46th jolnt IU8M84EBS4ABMB Congres8 Education Acti¥itRs FEBS Education CoMMee organised its tradItn81 spec¢al and poster sessions joinuy with IU8M8 and an èducation plenary jointly the Congress Organiser5, at the 46th joint lUBmEB&PABm8 Congress. 11 FEBSIIUBMB Speaal Session on Edueatson entrtled 'Where do WÈ go from here? Experiences, lesson5 leamed and projections for hybrid post£ovit1 education, wth speakers from Spain, Australia and the UK. 21 Education Ptenary lectuie entrtd 'Beating to a diffarent drurn. how can education beeomè rèlèvant again?, by Boris Jokic (Croatial 31 Postsr Session on £dUtiOn- 22 poste We submrfted on education. 41 FE8S Special Session on Research and Cafftr Ski1I5. ganISed with the FEBS Wor"ng Group on the Careers ol Young Scientssts. Contribution to FEBS Network Several posts were published on thè FEBS Netswrk Educator channel in 3)22, includirrfJ." 'Decreasing fear of failure and in¢fea5ing meaningful intèra¢lions with students. 'Integith"ng Augmentèd Rèalty into bioscieneè educab"on' 'Stepping outwde olthe catch-22- tips foi bioscientists comrThtted to education. ain recggnrtK)n lor your innovabons usirKJ dwrtal tools In saence education. 'Using Pèbblepad for e-portfdios in the ral scEnces' 'Visual asynchronous teaming terIals.. examples from Edpvzzle and ThingLink' 'Translerable skills education in the biosciences". weparing our graduates for life outside uniwrsit Educatlon Committee Wortt$ho FEBS Education Joint Workshop wilh HOBMB Icroalian socw) held in ¢)ctgber 2022 in Za9reb, Croalia. ¥th the htle'Designing Educational Reseaich.. FEBS Education Commrttee also sponsored an education workshop organised by tha Tunisian Education Ainbassador. Hatem Fakhlakh. ented 'EduCatnal Consid•rations for Training, on 7 Decemb¢r 2022. Contributions to the 2022 IUBMB-FEBS•ABMB Young S¢ntists' Forurn ThÈ Educats)n Convnrttee participated in fvdo prathcal sèssions of the 2022 IUBMWFEBWABMB Young Scientists. Forum (held in Vimeiro. Portvgal to the joint CoThJressl. enlitd 'Career Skills Practical Éxercises.. Contributions to FEBS NAvanced CoUS FEBS Educats"on Committee chair gave a Iraining le¢ture on the science and art of writing a scients"r artic at the FEBS Advanced Course'Redox terationS and Cellular Responstt". From Signalling to Interventions,. I25 September 2022 Spetses Island. Greece. Two workshops lon how to wrrte a scienfft paper and h)w to present y)ur wothl wo1& TrIed on at the FEBS A¢fvanced Coufse .360" LYSon". from Structure to Genomics. from FUndn to Diseèsè. 4 - 9 October 2022 Kusada5i I Izmir. Turkey. Integration The Working Group on Intègratb)n IWGII. whh vms chaired in 2022 by Prof. Jerka Dum, continued its outreach and support for scEntists In European wuntries with econornic challenges andlor no existing or a¢tNe biochemical socety. as well as aclmtses for Inte9rknn and collaborat) ty¢ all FEBS socreties. ActiMts ofthe WGI dn9 2022 induded.. working Wrth the FE8S Fellowships Comftmttee on the ColkboratNe Developmentsl Scholarships criieria for the exeluswt benefft of PhD sbjijents in eertain FE8S eountrTres Wrth HINARI IResearch4Lifel status.. supporbng the three societies ol Estonw, L8fvN4 and Lfthuania wrth their organisation ofioint meetings. wrth their next meeb.ng held in Tallinn. Estonia in June 2022", launch ol the Member Sotièty Representative5 IMSRS) in(¢iative'. comm?ncing in July 2022, this initiative involves one MSR from eath FEBS Jrmber sOcty to be the maH) link bttween their soeitty and FEBS to .Pago 8
THE FEDERATION OF EUROPEAN BIOCHEMICAL S(xieTIES IA Company Limited by Guarantsel TRUSTEES. REPORT (CONTINUED) FITHE YEAR ENDED 31 DECEMBER 2022 strengthen the relatvnship, as well as providing a voice to keep FE8S infornd and the opportunrty lo neork wrth the othef MSRS via a dedicated FEBS Netswrk channel, in online meetings and in person al the annual MSRS meeting held in conjunction wrth thè FEBS Cong¥Èss 2022 was thè first pilot year ofthis inrtiabve. FEBS provided limrted support to each MSR for th$m to attènd the Con9iess. Al member societies lexcept the suspended Russia and 8elarusl have nw4 nominated MSRS and 30 ofthè 37 MSRS attended the Congress in 5b0Th and MSRS rrEetin9. the WGI Chair attended the FEBS-IUBM8-ENA8LE kick-off eting in Cdogne. Germany in May 2ry22 and the Education ComrThttee nding and Education Ambassado ting in Izmw. Turkiye in May 2022. the WGI Chair actively on new inrtiatNe5 to increase collaboration and engageThnt wrth FEBS member sotseties and ¢¢ll#bo¥ated wrth olher eonynrtiees and working groups. As part of thè WGI aLIMties and the FEBS Congress, finaneial support was gwen under the 'Sprinzl Seheme, wrth a SO% registration fee discounl to scienb"5ts resident Istudyngthrkingl in Arrrenia, Bosnia and H8rz89ovina. Ggorgia. Moldova. Morocco. Serbia. Tunisia and Ukraine to attend the 2022 Congress. Women in Sclence The planned actmbes ol Ihe Working fyoup on Women in s"8nCe (WISE) wth Prof. Ceeilia Arraiano as Chairperson in 222. wefe as fdl¢)ws- The FE8&EM80 Women in Saence Award, in rts fffteenlh year, recognises and rewards the exceptional achievements of a female researcher in molecular OlOgY giving particular attention to the previous fve years. Winners of the award are role models who inspire future 9eneratr.ons ol wOffn in science. The 15th meeting ol tr¢ FEBSEM80 W(Ynen in Science ArI ¢ommtt$e took pla¢$ m February 2022 to reVW the nominations receNed fof Thè FE8SEMBO Wown in Science Award 2022. Many of thè candidatès, Cvs weie excellent. Aftèr discussion. the working 9roup votèd lo award the 2022 prize to PTof. ETin Schuman (Frankftjrt, Gernwnyl, for her •xcepbonal contributions to our understanding ol nèuronal cell biobgy. The awafd was presented durin9 the FEBSEMBO Women In Sence Award ledure at the IU8MB-FEBS-PABMB Congress, held in Lisbon, Portugal in July 2022. The working group also pknned thè folbM"n9 events at the Congrw" al the FEBS Spec1 Session on 'Gendei Issues in Science. with four inmted speaker5 and an open dI5$S1on. bl Ihe TheorkIn9 lunch for 50 Congress parttcipants to discuss Women in Science issues OBJECTIVES AND ACTMTIES FOR THE PUBLIC BENEFIT The overall gbjective of FEBS is to contribute to and prorrKJte the advancement of research and education for th& public benefft in Ihe sciences of biochemi8try, mlecular bKJty and related disciplines. As indicated by thè spo¢ifi¢ key objectives of FEBS set out above under Dbjectwes.. FEBS doès this particularfy through". funding forums for presentation and discussion of research r8suMs and r•lated areas of interest al rts large annual Congress, Young Scnbsts' Forum IYSFI. FEBS Felltsw5 Meeting, Special Meetings and other Advanced Courses.. promots.ng training through lectures u)urses. w9rk5htsps and prarti¢al courses ol its Advanced Courses programme, as well as rts èducab.on workshops., and supporting participation of pfomising young scientists in these evenls throu9h YSF aw8rds. Youth Travel Fund grants and Congress bursariès., facilitating and suppth.ng the exchange of s¢nlthc infornwlion betsveen biochemists and moleeular biologists especially in Europe and other countries of FEBS Consb"tuent Societiès principally through these foiurrts and rnechanlsn, but also through Constr(uent Soeiety meetrngs (National Leclur¥ stheiiiel, FE8S3+ meeb'ngs, FEBS Fellowships (which protTr)te nbIlty), and s¢hemes to 5UPPOrt integration of bioscientists working in economicalty disadvantsged countries ofthe FE8S area.. providing skn'pends through rts Fèllowships progrtmme to all research to be carried out in host laboratories by talented early-career scientists." offering high-qualty publication of research findirss for both authors and readers through its four internatn81 molecubr life science ioumals. Page 9
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarant) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 OECEMBER 2022 Through the many aCINe5 of FEBS ouUin•d above. the beneficiaries of FEBS include seièntists at all levels directty enga9ed in resear¢h educatKn in the mole¢ylar life styences, and ulh"mately humankind acros5 the globe through the contributions of these areas Clf suence to human h¢aMh, agri¢unure, biotechnology and related a&$, and enriCh0t of human kno%èd9è. FEBS vtholty owns r(s intemational ioumals, are ol importance to FEBS bolh by directly contributing to its objectives and as a source of income to support rts othtr purposes. FEBS follows all directives on Open Access publishing from the UK, EU and rekvant research bjnders across the worfd. of the FE8S publicatn5 - FEBS Opgn Bio and Molecular Oncokngy- are fvlly open access. tts two hybrKI journa15 - The FEBS Journal and FEBS Lèttèrs - offer author5 open aecèss optnS, often wrth no ¢Jireet cost to authots at Instrtuts'ons wth a tran51ormatK>nal agreement In addth"on. authors are ab to deposrt accepted research artic$. as ¥equired by funders. in institubonal repositors, through which they are accessible to the public. and all published arti¢les in our Joumals are freety available after 12 months to all reader& FEBS events are nomialty open to scientists throughout the worfd. Reupients of FEBS grants for fellowships and for 5UPPOrt of parttcipatson M) mtetings are norrywlly required to be members of FEBS, Constrtuent Socieknes where membership criteria are those expected ol leamed sOctIeS) and reSent wrthin the FEBS area of Euiope and neighbouring counthes. Som? FEes pith3raTh partsculaty benefrt disadvanta9ed Scienbsts. The trustees confim that they have referred to the guidan cofttsin¢d in the Charty C ommi55ion's general guidance on Publ benefft when rtn9 the organi5thon's aims and objectwes and in planning luture actiwts"e$. Grant Maklftg Policy Thè overall objectNe of FEBS is to contrit)ute to and promote the advancement of reseafch and Èdueation for the public benefit in the rn0¢1ar life 5¢iences and related disciplines. Polics for key grants awarded by FE8S to achieve these goals ale oUtIed below. Fdlowships As part of our commrtment to young scntists uThJer the FEBS F¢1knhlP progfam set up in 1978, and to further research in the molecJJlar lifè s¢i¢nces, wo offèr Short-Term Fellowships tg members of Constituent So¢ieties, as wèll a5 Summer Fellowships to profftsin9 MastèrslPhD students. The FEBS Ex¢ellen¢e Award program vrd5 launched in 2021. It is InteIed foi early-career lenSt$ who have been Pls in their Host Instr(ution for at least one year and are in a salaried capacity. As part of our Fel1¢Yh1ps program, we a150 offer 5¢holarship$ designed exclusNely for members of our Con5b"tuent Societies based in FE8S counliies wrth HINARI IResearch4Lifel status. Ojr Fellowships are intended to allow Membe of our Constituent Societies wothing in FE8S country to work in a Paboratory in another FEBS country. Eligibilty critella FEBS F¢lhvships a set in detaId guidelines on the FEBS websrte. The initial applications lor Fèllowships are asst55ed on rrerii by the FEBS Fellowships Comrttee. Within three months of corTyletion of all Fellowships. awardees are required to prepare a final report on the work carried out during the tenure of the Felbwship. Similady, EXllenCe Avrdrdees are asked to provide both a seientfft and a financial report to be digible lorthe 2nd and 3rd insta1rrnt5. Grants for organising FEBS Advanced Courses Grants for organising FEBS Alan¢s Coursès lincluding kcture coutse5. workshop5. practical courses and special meetings) are awarded to senior scientists by the FEBS Advanced Courses Committee on a competitive basis Reports (including scientific and finanuall from the organisers are required wthin 3 months afterth¥ event. Grants for young scienlists attending Advanced ¢¢urses students parti¢ipaling in FEBS Advanced Coutses lineluding ledure etsurses. wowkshop5 and practical courses) may appty for financial support through the FEBS Yovth Travel Fund {YTF}. In 2022. grants were made to persons travdling from their current country of Te5idence to another country. mostly in the European area. Page 10
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) TRUSTEES. REPORT {¢ONTINUEO> FOR THE YEAR ENDED 31 DECEMBER 2022 Applicants for these grants shoukl nollnally be registeret1 as a student at an institution of higher learning in a country where there is a FEBS Constituent Socbety or be %wthin fve years of having completed a Pho thesis, be a member ol a FEBS Constrtuent sOcty, aThJ not have reeeNed a grant from the Youth Travel Fund to attend an Advanced Course in Ihe ¢uThenl or preceding ar or received a granl to attend Ihe Young Scientists, Forum in the currenl year. Candidates are shoruisted by thè Coursè organisers on TrlIt. Grants for oryanising th¢ FEBS Congress and FE8S3+ m¢¢ting$. and requests for National Lecture support FEBS alUateS bids for organisin9 ts yearfy Congresses and a150 FEBS3+ mèèlings. as well as raquasts from Constituent societs.es for N*lla1 Lecture support. aOrdIng to their quality.. the administrative rtsponsibilrty for these Is in thè hands of the FEBS CrgreSS Counsellor (Prof. Miguel A. De la Rosa In 20221. Grants for attending the FEBS Young Scientists. Forum and cong5$ IYSF awards) ReCIpntS of YSF awards arè selecled by the Chair of the Worknng Group on the Careers of Young Seientsts Ilrene Dlaz-moreno in 2022) and the local organtsng commrttee.on ftrit. wth eligibilty cnteria that normally include.. i)being a PhD student or postdoctoral lelbw wrthtn 5 year5 of Iint5hing hislh?r PhD at an instrtution of higher education in a Country where theie is a FEBS C£snstituent Society.. ill bein9 under 35 yèars ok¥." iiil being member ol a FE8S Conslrtuent SOC.. not having attended a recent YSF. and not having received a yo Travel Fund award in the 5arre year. Congress burwi¢s Reeipient5 of bursaries (which offer financial s¢Jpport with registration. travel and accomnl)datn costs for the Congress) are selectsd by the host So¢ty ofthat yearfs Congress on meri( eli9ibilrty Criter similarto those fof YTF and YSF awards. Page 11
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA CoThyany Limited by Guarantee) TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2022 Achfiev•ment and rnian¢e Thi5 5edion sunw))aris&s and assesses our prinopal achievements in 2022 against the forrnal obj8LNes of FEBS. More detsiL8 ol the activities included in brief here can be found in the 'ActMties' sectyon above. Objective 1: holdlng and arranging congrèssès. trairting and educational courses on matters connectéd with biochemistry and molecular blo1Y and related disciplines Acl•vgmpnts FEBS Advan¢•d Courses In 2022. FE8S to several Courses YltyL hlgn SaenfjT nient ana so YrF ants 10 oiiow parlclpal7 ol re5earchus at the FEBS course5. Ini FEe>EM80 Leclure Cwr5e5. 2 Prdctth arm1 Leclure C¢JurEe5 were as pusonai evert8 Ouflng 2022. funoin9 tefi11. (xllne dolabase f¢r apF4TrtXY atKI ¥Eb5ites th<#JLKvJ cdIat)tstrts EPAPL) aTrJ IV8M8 cNIM. FE8S3+ M••iiTro1'. anie. Sn K1ay 2022". IrE NthrEs 0ftGe. meelit)g bosied ty the 8iLKknI SAxiety IUK). Suwt ty xnli5tS In EonIa. Lama. LftNMnra. lE(vn these FEBS CS1eN etieS. see 'Xt C4)nslitUEnt Scrjety events. seciion lor ana sTr.. Tllnn Estorma. 2022. Ine h05reiJ fflewer sweiies orLakna a¥J LThban poh)rt meattenaarKeorywYJ s¢ientiSts frOrn ¢X partUPallng Scrles. 1st Youny SCIentts Fovum IYSFI and FEBS ¢ongrE%: e 21 Youry ScienbSI Fon¥n. In IUBMB wxl EBS. 1001( a(e. The YSF lnrJ o4er 100 PhD an Cre$S 6 ILwvJea fry FE8S YSF ai%ras. In ition. Fe8S supports pjrtkjw a rge olyowYJ SCWis7s 115 anrw)I Congfe5$ unclon IUBM8 PABFAB. The annual FEBS cong.ress provioes a ptratf Icf interrwlKYbJl s(ientlfic exchallgp and Sr¥se$ I r¥A¢st ae¥dopmen15 In b51. neculai knDb9y and areas. The Congress comprises pnary ieciur&8. syrnptss poer Ssk)n5. IWYK5Th0PS and Olher MlS rMI re*ateo tot¥¢S. The c4ngRss Is wo In counthe5 a Con5tMueN scety of FE8S. Page 12
THE FEDERATION OF EUROPEAN BIOCHEMICAL s¢XIETIES IA Conwany Limited by GuarantÉel TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDE031 DECEMBER 2022 ObJ•ctive 2.. l•ellitatin9 and supporting the exchang¢ of scientiflc infornution ljetween biochemists, molecular biologists and lenti$l$ working in related discipllYs g•nralty and especially in Europe and other ¢ountries of Con¥tituent Societies A¢hi&v•m•nts FEBS Conor•ss. Ath7thed CouThes an(1 EdUuW0rS L•¢tur•rs for Constityent S•¢i•ty aAa Olh•f sclent611¢ fflthtrys Mylk)rwl L&lU lo s)elES ernational reellr¥Js Turtya aThJ TLMW. other sponsorsnip rfeetrgs EurotE. Kfftiui intun•irna UgartzKs * ylew FE8S M¥s. Aehlevem•Thts FEBS FellWlP$ FelllPh8 (see Ctiecb4E 3 WGI 5thm•s Supphyt for (rr¥Jn ol ImrNIe Si15[$ In Ewfwn s¢ciety Ihrwjh S$. the Ccfigress'spnnl SU. EaLfa WoNsrws CDS Fdknws as a5 enC£ragIThj me eStatytsl1xN ofngw50fLes ano FEBS. Objective 3: fa¢llil•ting and supporting the training of young ¥cienti8ts in rese•r¢h. in the form of fellowship$ Athiev•m•nts strt-Terrn Fdlow5hlp L- T•Th FelJOWJThIps 5 LT In PCGL gary Iwniis. ACC(1$ ft¢mèitsr part of FEBS e¥wLthe TMS ¢K(Wl¥3$ aiscertln as e12021. Exedi•ThC• A¢ 19¥)51. St[551. Iry rnkSI be Fecrorrizeo sctnusts Inthe F•11¢y M••ttng Imd m Vimeo. Portw 2Q2z In the Young Scknitsis Fotwn) 17 pJrrEM r LTFS Ihe w)vitth. parttwants iwieo 10 partwie. No sewon {1Ure a5 ortyctjrrent past FE8S Lor Terni F•ifpw5 are eiyibie. The c113t costsaTe Page13
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Comp•ny Limited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022 Objective 4: oryanislng the ediling and publication of sci•ntSfK research and educat•onal mthrlal In blocMIstry and mol¢¢ular biology and related dlseiplin¢s in a W¥15DIry The current Publishing Agreement between FEBS and I1Y run5 201&2023. The eight-year contrad is based on revenue share. guaranteed incon and SFcl support for the FE8S Nets. FINANCIAL RW4IEW Journal income and costs Total income from roya'e$ in 2022 was 0.2% hMJher than the royalty incon in 2021. The totsl costs lor the four FEBS journals. FEBS Journal. FEBS Letter5, FEBS Open B) and Molecular Oncology in¢ased by 13% in 2022 frorn 2021 lexduding forèign exchange) Thèse costs are the ¢Jirect costs and support costs induding èmployees work on the joumals. The increase ts due mainly to an increase in joumal payroll costs. Distribution of •xpÈnditure on FE8S activities In 2022. Fellowships rffAined by far the highest area of charitsble FEBS spending 4894,000 {4817,000 in 20211 then Advanced Courses, gross Course grants and F$ totaling 4506,oC,.1-97.CJ) in 20211. PirLes and awards for excellent¢ in molecukr Irf¢ scien¢e5 totaled 439,0001430,000 in 20211, and fijnding of lecturers for meetings within and outside of Europe totssed 454,OCKI420.000 in 20211 including h¥0 FE8S 3+ netings. Several other areas of FEBS work induding edUtIOn workshops, science and SoCty sessions, and 'integration' inrtiatsves, Te undertaken for 8,[KIl16.LO in 21r211 in total. Governance and support costs The senior scntists who serve as FEBS Offi¢er5 and rrembers of FEBS rnrThttees all work pro bono, 8nd the holders of key positiofts In the FEBS Exerxrtwe Commrttee generousty devote C0nsN1erab ts.mè and energy to FEBS activfa'es. There are a small numbèr of sUPPOrt personnel working in111 the FEBS Central Administration OffKe dealing with eentral administration and corrmunutKJns. {21 the FEBS Treasury orrice dealing wth finala1 matters. and 131 those woth.ng the Fellovrthips and Athanced Courses Commrtttè Chairs to support their work and those ofthe ¢onNnrttees. The total govemanee costs- including Ihe expenses assoeiated wrth higher4evd commrtttes Icouncil. Execukn"vè and Finan¢el vthin FEBS. Central Administrab"on Officè. The Treasury Office and Secretary General expenses, as well as audrtor and other lees amounted to 18%123% In 20211 of th• Se of charitable spending in 2022 (notè that these governance costs are not included in the lotal for chartsble spending). An indieab.on of the sup( eosts invofved in runnin9 the b¥0 acmies of FEBS with Ihe high•st expenditu[• can be gNen by the commrttee expenses as a peicenlage of the charrtable spending in that area". this was approximately 7% in 202214% in 20211 for Fellowships, and 11% in 2022120% in 20211 lor knanced Coursès lallhough these ureS exclude governance costs of central admintstrabon at the FEBS Treasury orricel. Support Costs for th6 Journa15 are covèred in'Joumal incorr and costs, above. Investment performance In 2016 FEBS reviewed its investments and the Finance Corrmrtt¢e deuded to hohl a tent1er for the management of the inveslrrents of FEBS. JP Morgan Wd5 the successful tenderer after an intensive seCtIon process. The tenderwas conducted by the Finance ConYNtlee, plus the Chair of the Fellowship Committee, with the assistsnce of an independent investment con5uttant. By 31 0ecembeT 2017 the investment portfolio had bèèn moved to JP Mor9an. For th• rrKJnths to the 31 Det¢mber 20Z2 Ihe inveslment wJrtfoh'o held at Jp Mor9an had a rebjrn of-13.09% bss1+14 6 % in 20211. Page 14
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarantee) TRUSTEES, REPORT (CONTINUED FOR THE YEAR eNDED 31 DECEMBER 2022 PRINCIPAL RISKS AND UNCERTAINTIES The trustees have a duty to Idefity and ¥1¥ the nsks to which th• charty ts èxposed aThJ to ensure appropriatè coniiols are in place to provNle reasonablè assurance against fraud and erroT. Change to JoLFrnal Income In add.thn to directly fulfilling one ol the charilable objectNes of FEBS Ipromoting and dissemining scientific research and ideas), o¢Jriournals prowde a source ol income to fund FEBS, oth•r charitsbl• work. Future income strea0 are uncertain due to major changes in the pUblh1Trg sector. The income fron) journal publishing 15 changing as library contracts nw¥e from $ubw"ptwJis to open acces$ publi¢ion fees or other publ$shg modeL8. FEBS is addrg55ing these concerns by {1) rts policy on reseNes (see bek)w) so that some fijture iOrne can be dtnved from inVestntS and121 ts negob'ated long4errn contract wth a commercial publisher whieh, in turn. is negotiating dèals library and bjnding consortka for Read and Publish I Publish and Read access to the FEBS pre55 journals. A group of funders called cOAlition S mainly from Europe, announced an initiatr've (called Plan Sl in September 2018 requiThng their grant holders to publish only in full open access journals from 2021. From 2024 all publication in¢orre voll transition towar¢Js fvll Open Access. The FEBS Publications Comffittee has reviewed its consequences and made a strategic plan on howioumals ean adapt to new publishing requirements of Plan S 5UPPOrted authors. Return from investments Up until the end of 2017 FEBS followed a standard inve5trrenl policy wilh investment in 30% bonds and 70% eqU"eS. Since Tnoving the InveStnt management to JP Morgan, FE8S ha$ made $omè changes to its policy wth investments eurrently 131 May 20231 allocated to 60% equi(Es, 27% ffixed it)com• and cash and 13% ¥lternativès IPE is limrted to 8%). The perlormance of FE8S' investments is monrtored gUlarty. Tha performance of thè portfolio held at JPM for the year ending 31 December 222 was-13.OVh114.6% in 20211. All decisions about investments are made by th Finance CommrttÈe. as delegated bythe Executwe Comnrtte¥. On OcCasn the Finance Conwnrttee may seek further approval from thè EKeortNe Cornmee on significant investment commitments. Internal Controls FEBS has an environryEntwhere improvemnts to the systems and PToeesses are encouraged. Tht Finance Committee is responsible for maintaining proper acctyjnting records which discbse with reasonable a¢curacy at any time the financial pOsrtn and to enab them to ensure that the finanual statemeThts comply with all ststutes and regulations. FE8S' controL8 inelude regular inteinal and eytemal oversight and checks. Controls and procedures are appropriato lor the or9anisation's soe and operation. FE8S uses automated aecounting sofmre from a large, reputable supplier and The Treasury dèpartment has several processes to ensure the appropriate use of frjnds. the rnana9èffnt of the accounts and recoiding of all transactions. Dub"es within the Treasury are separated. and Tobust systems of overSht and authorisab.on are in place. Impact on overall objectives The success of FEBS In promot¥ig the a¢fvanceff*nt of research and educab.on for the public benefft in the sciences of biochemi5ty. mokcular bKJk)gy and related disaplines 1$ ¢arefvlty monrtored by stringent peer review and other methods. PLANS FOR THE FUTURE Reserves policy Thè total value of lunds held by FEBS at 31 December 2022 was É89.3M1É99.2M in 20211. None of the funds re restllcted ftjnds or unavailable for the general purp9585 of the charity at the end of the reporting period and no material affKJunts have been dèsignated or are otherwtse commrtted as at end tsfthe reporting penod. Page IS
THE FEDERATION OF EUROPEAN alOCHEIAICAL SOCIETIES IA Company Limited by Gu•rnnw¢l TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENOED 31 DECEMBER 3022 As at year end 2022. aFpr0MatY 83% coukj be realised in lewtr than 3 days. was in investmenisthal may e realised in 10 years anil the re51 had lThescales. vp lo 4 monlhs, in which the a55ets may be iealised. The Inveslrnents in private eqLrity and inlrastnjaure canrnl be Squtdated. These in¥e5tmenls wll be hewj foi up 10 10years and vp lo 8% v4ill be hdd In private equily and 5% nfvaslruclure in FE8S' main pKtrtloh"o. The Trèasurer of FE8S' regularty revws the r¢rfomance of FEBS inve51rnents during the yeaf. Significant ¢han9es in Invesirnenls and Ire31menl of funds are discussed approved by Ihe FE8S FanCe Committee andwhere apprcpriale. are sutffiitted fN hmher apkwoval from Ihe FE8S ExecutN Committee. The FE8S fftses polw albcates É4M one Jea¢5 essen lun¢Jfftg artd Ihi5 is held in cash al Ihe ban The FEBS Tw51ees aFwo¥d the hance1 of Ihe irNe51m8Trt Portfol lo reach a value that rnay seneraie funds tt> offset polentrdl changes incrfft due 10 Ihe puWi5hing modes. The Income frtyn tl portfolio in addition to royatty income v4iH ensure thal FE8S exists in Feltulty prowth'ng lunding for Ihe wnnsr olthe joumals and ils Olher thawiiable ad1¥15. Impa¢t of COWD-19 In the short 10 dIuM term COVIt>19 not hav8 * wrwact on majLw Sour of FEBS, irne which 1$ Ihe royalt$ frcffi FEBS. joumals. The fnanoal performance of the instmen1 porrfolio gave an investment performance of 14.6% in 2021. W¢ylJ ev1$ including the inv3sion ol Ukiaine by Ru55ia. have had a negalwe I4£¢ on FEes vestMents 2022. wih a l¥1 of 13% Yabjg ol FEBS. main portlolu?. FEBS did nol inDJi any addilwal cosls due io COWO 19 and ¢ls day-ldaY OFeralKJnswwe carried on without a major inpa¢i. No employe5 Ot FEBS were OUght and no governmenl granls were sought rece&ved by FE8S relation to cov119. One of FEBS charilat aims Is 10 5UPPOrt lrfe SenceS through Jis events and in 2021 these a¢tiMlie5 were curta4ed. a5 they were in 2020. In Ihese cases. the grants have not been paid were rolled over lo fvnd acbWlS in 2022. AS a resu expeTr(htuie tr 2022 is 9her due 10 the nwnter of events poswned from 2020 and 2021. Future tments and plans for other rea$ of FE8S TAorf¢ We now have firm arrangements for a programme DfAnftual Congresses UMII 2024. as these involve sbantial fts3rd pkAnniro. Empendilure on AdVand Coufses up lo 2024 the ¢os ol Ihe FEBS EXCelNCe Awards e includeij in our budgel5. th regard to future activrties. we also Corfinuiw to forge cbser bnks wilh relaied European and worl1 organi$alDn$ Ihai cor MnligutyJ51rf3pplng areas of molerJJlar lrfe $CceS le.g. bM)physics, ffcrobiol¢4y. immunology. ¢anorl with le aim ol rnaxtrrdsg the use ol our irnpacls and rescoJrcÉs. Con¢luditt9 FEBS has continued lo operate suceessfulty in promoliiig the aEfvancernenl of research and education f¢y the public benefit in the Sciences of bi¢xhemisiry, molectslai and rdated d15tiplines, and its cur¥enl strategy foi ils lts)*lerm sunnval is progress9 smoolhty and accLYding to By mthng wilh 115 re5erve5 FEBS will be in a posiltyl lo prowde Sur io many researchers in year$ 10 come. Appmve¢J by order of Ihe members 01 the board of Twslees a$ signed on thwrbehalf by. MOeLaRo Tru51ee Date.. 31 August 2023 Page 16
THE FEDERAnON OF EUROPEAN BfocHEMICAL SOCIETIES IA Company Limiltd by Gunn¢e¢l STATEMENT OF TRUSTEES. RESPONS181LITIES FOR ThE YEAR ENDÉO 31 DECEMBER 2022 The Tw51ees (who afe afso the dId0 of the Company for the puiw$ of ¢thnp•ny bwl are responble f eparing the TrsteeS. Report and the financial slatement5 in accDrdaTrce with applicabse and Untled Kingdom Ac¢ouniing siandards IUnLted l&ThJdom Genera1yA¢ceptedAccJnll9 Practice). Company law reouires the Trustees lo prepare finanoal statements for each finanaal year. Under company law, Ihe Tiknsiees rnust not approve the financkil slatement5 Un$$ they are 5a115fied that they give 8 liue and fair ew of ihe st3te of af13$ of the Company and of rts Inccrfning WesJrC2S and apicatiOn of iesources. icJu(ng its income and expenditure. fry that piod. In piepaiing these financial statemen15. Ihe Trts51ee5 are reouired lo. se wilable accounting FO1je5 and Ihen apptyth?rn corF%stenlty." obser¥e the methods and prinoples ol the CharitQ5 SORP IFRS 1021", make judgmenis and accounting estymates Ih818re 0$onable and t. State Whelr app&cable UK AccJJnting Slandards (FRS 1021 have en foluwed. sut¥8LI lo any matwial departures disck)sed arrfl explained In the financol swements", prepare the finanErdl slatemenls on the grj tontewn basis Un5$ it is lnapkKopvte to Pfesumt that the Company will contirKR In busine. The Tnjslees are responsible for keeng ajequate attounbng Tecord5 that are 5uftiuent 10 Show and explain the Companls transact5 and disdose wth ieasonat4e acturacy at any lime the finanaal posibon of the Company antl enab Ihem lo eD5ure Ihai Ihe fiTrarKial 5tatemen15 cornpty %4ith the Compan$ Aa 20Cfj. They are also respOnse foT safeguarding the assets of the Company and hence for taking fea&on8è step5 lor the preVenn and dttecbon of fraud other iireguia1iS. ApproN*d by order of Ihe Membe of Ihe l)oard of Twustees aTrJ wgned on its behall by.. M Oe La Rosa Trustee O?te.' 31 August 2023 Page 17
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guaranteel INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BICCHEMICAL SCCIETIES OPINION We have audrted Ihe financial statements ol The Federats'on of European Biochemical SV&"es (the chairtable compan) for tre year ènded 31 December 2072 whh eomprise the Statement of Financial Activrties, the BaL4n¢e Sheet, the Staternenl of Cash Fk>w5 and the related note5. induding a summary of sNJnificant accounting pOIles. The ffinan¢ial reporting fra[rS[k that has been applied in their preparation is applicable law and United Kingdom Accounbng Standards. Including Finanual Reporbng Stsndard 102 The Finanaal Rèporting standard applicable in the UK and Rèpublic of Ireland, (Unrt•d "Ag¢JOrn Generally Accepted Accounting Pradicel. In our opinion the financial ststewents.. gNe a true end fair VI ofthe stste ofthe chantablÈ coryanls affairs as at 31 Dècember 2022 and of rts incoming resources and application of resour. including rts income and èxptn¢Jiture for the year then Ènded". havè been prop•ty prepared in aecordance with UThted ngdorn Generally Attèptèd Accounting PractKe'. and have bèèn prepared in ac(iJr(lan wh the requirewnts of the Conyanies Act 2DC6. BASIS FOR OPINIC Wè eonducted our aut1rt in accofdance with Inlernat)naI Stand8rds on Auditing {UKI IISAS IUKII and applicable L8w. Our responsibilittes underth05e standard$ are furlher described in the Audf(or5' respon5ibilrtte$ for the audit ol thè financial statements secbon of our report. We are independent of the chantable company in accordance with Ihè èthi(al requirements that are r*vant to our audit of the finanaal stalements in the United Kingdom. Including the Financial Reporting Council'5 Ethical Stsndard. and we have lulfilled our other ethical ponsibilrties In accordance with thesè requirements. We believe that the audr( ev¥Jence we have obtained is Suffirient and approprk3te to provhle a basis for our opinic. CONCLUSIONS RELATING TO GOING CONCERN In audrting the financial ststements, we have concluded that the Trustees, use of the going conc•m basi5 of aCCnting in the preparnb.on ofthe financial statements is appropriate. B85ed on the wort we Mave performed. we have not Klents"fied any material uncertaintS relating to events or conditions that, indNidualty or collecbvely, may cast s¥nificant doubt on the charitable companls abilrty to continue as a going concern for a peiiod ol at least month$ from when the fin¥n¢ial statements are authorised lor issue. Our responsibilrtie5 and the fesponsibdth'es of the Truste¢$ wth resped to 9)iTrJ concern are described in the relevant secbons ofthB reporL Page 18
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A C4xwy LI¥ted by Gu¥anteel NOEPENDENT AUOITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN 810CHEMICAL SOCIETIES ICONTINUEDI OTHER INFORMATION The other information comprises the information included in the Annual Report clher than the financial ststeNnts and Ouf Audrtors. Report theieon The Trustees are resptsnsiblè for the other information contained within the Annual Report. Our opinion on the finanual staterrnt5 does not cover the other information and, exceptto the extent otheTh¥isè explicitly stated in our ieport, we do not express any fom of assurance conclusion thtreon. Our responsibilty i% to read the other informabon and, in doing 50. cOnSeT whether the other informaion is merially inconsistent wth thè finan¢ial stem¢nts or our knowledge obtained in the course of the audrt, or othewse appear5 to be materialty rnisststed. If we identify such material ineonsistèncits or apparnnt material misstatements. we are required to delefrritne whether this gjves rise to a matèrial misstatèmènt in the financial statements thern5elves. If, based on the work we have performed, we conclude that there is a material m1551alerrent of this tsther informat'on. we a reqvired to report that facl We have nothing to report in this regard. OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006 In our opinion. based on the work dertaken in the g)urse oflhe audit the in1M01[0n 9Nen in the Twstees. Report for the financial sEar for whth the financial $18lements are prepared is consistent wrth the financk?I ststements. the Trustees. Report has been prepared in actofdanee wth apoabbe legal requirements. MATTERS ON WHICH WE ARE REQLIIRED TO REPORT BY EXCEPTION In the It of our kno¥edge ant1 understandin9 of the charrtable company and its eNronment obtained in the cou¥se ol th6 audit. we have not klènth"ffied rrotellal misststements In the Trustees. Repo We have nothing to report in respect of the matters in relation lo whth Companies A¢t 20C6 require5 us to report lo you rf. in our opinion". adequate accounbng records have not been kept or retums adequate for our audrt have not been receNed from branches not wsited by us." or the finaneial statennts arè not in agreeThnt with the accounting records and returns.. or certain ¢Jisclosures ol Trust•e$' remuneration specffied by law are not mat1e,' or we have not receNed all the inforrrrats.on and explanations we require for our audrt." or the frustees were not entitled to prepare the financial staterTEnt5 in accordance the small companies regime and tske a¢fvantage of the Small companies. exemptions in praparing the Trusteès. Report and from the requirement to prepar¢ a Strategic Reporl Page 19
THE FEDERATION ()F EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llftwted by Guarantee) INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES ICONTINUEDI RESPONSIBILITIES OF TRUSTEES As explained more fully In the Trustees. Responsibilrts Statemen( the Trustèes (who are also the directors of the charrtable company for thè puiposes of company are responsible for the preparation of the financial staternents and for bwng sabsfied that they give a true and lair view. and for such internal ntrol a5 the Trustees determine is necessary to enabk the preparatscffi of financial statements that are free fiorn rnaterial misststerrenl, whether due to fraud or error. In prèparing the financial statements. the Trustees are responsible for assessing the chartiable companY5 8blity lo continuè as a going concein. di5¢bsing, as applicable. matters related to going concern and using the going concern basB ol aco)unting Un$$ the Tnjstees erthe( end to IUale the chantable eompany or to cease opefations, or have no reali5b"c atternative but to do so. AUOITORS. RESPONSIBIUTIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS Our objectNes are to obtain reasonable assurarte about wher the financial s18lemenls a5 a whole are tree from material misstatement whethei due to fraud or error, and to issue an Auditors. Report that includes our opinh)n. Reasonable assuraneé is a high Ve1 of assuranc2, but is not a guarantee that an audrt conductèd in accordancé wrth ISA5 {UKI wll afvlays detect a mater1 misstatennt when rt exists. Misstatements can arise frorn fraud or error and are considered material il. indwidualty or in the aggregate. they could reasonably be expe(ed to influence the econonNc decisbons of useis tak¢n ¢Jn th¢ bast5 Of these [anCIal ststements. Irwularrties, including fraud, are instances of non-complianee wrth law5 and regulations. We design procedures In line wrth our responsibile$, outlined above, to detect matefial mi5statets in respect ol irregularrties. including fraud. The extent to which our procedures arè capable of ¢Jetecling irregulailbes, in¢luding fraud is detailed below. We obtsined an understandin9 ofthe legal #nd regulatory frarrworks through our acoJmul8led knovAedge and eon5iderabgn of se¢tor information that i5 applicable to the charitable cornpany. We determined that the most signficant art directy relevant to speufic asserb'ons in the financial ststements are those related to the finanrAal reporting framework including but not linNted to Unrted Kingdom Generally Accepted Aceounting Prath"ce. the Charf(ies Act 2011. Charits"es SORP. the Companies Act 2006. Data Prtste¢b"on Act 2018 and tax legislats'on. We obtsined an undèt5tsnding of the pKocedures and controLs over the charrtats eompanls operatKJns and disc¢Jssed these those tharged with govemance. No ffotters of fraud were brougm to our attentn during that dixussion. During our discussions wth management. they assessed these as being the noimal risks required to be considered by us as audrtors bythe Audrtirbg Stsndards Isuch as management overrNJe and revenue recognition) but confimed that no irregularrtie5 here occurred This was confirmed by our reVW of management meetings, audrbng management ovefride throu9h journal testing. and other adjustmènt$ to consider appropnatÈnes5. review of the financial ststements to ensure no unusual and l or Inexplicablè variance5 and general diSsslnS with managerTEnt during the course of the audr(. We did not ident any s3nfficanl business transactions outde the nom)al urS¥ C*lthe bu5ines$ operatK)ns. Our senior ststutory audr(oi has assèssèd that the audit team possessed the abilrty and competence to hlentify and reco9nise non-complpnce wrth the relevant law3 and regulations central to the operation of this charitsbk company. We have not ldentffd any addrtional laws and regulatsons Yrfhieh are central to the entitys Operatn$ and Wh we were not nots"f about, during the course of our audit ffi¢ldwork. Page 20
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Luhited by Guarahteel INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICALSOCIEnES ICONTINUEDI We beIve th our audrt d$ Capab of deteeb"n9 rrAtèri•l irregularrt4e$, ift¢luding Iraud. and our audit procedures were designed to respond to ri5k5 of matenal misstaterrent in the financial statèments. recognising that the risk of not detecting a matenal misststement due lo fraud is higher than thè risk of not detecting one r?sutting from error, as fraud rr¢y invofve deliberate Concea1nnt by, for example. forgery, misrepresenlatigns or through collusion. There are inherent 1imrtat)nS rn the audrt procedures prfomd and the further renw)ve¢J non-compliance with L8w5 and regulatn$ Is from the events and transathons reflected in the financial statèmènts, th¢ knss likely to bteomè awar¢ of A further desCriptn of our responsibilities for the audil of the financial staterrts is located on the Financial Reporting Counal's websrte at by1.fr¢.Qr .uklaudrtorsres nsibilibes. This eriPtIon forms part of our Auditors, ReporL USE OF OUR REPORT This report is made solely to the charrtablè ct)mpanls rrembers, as a body. in accordance with Chapter 3 of Part 16 of the Coryjanies Act 2006. Our audit work has been undertsken 50 that wè might state tg the charrtable company's members those matter5 are required to state to them in an Auditors, Report and for no other purpose. To the fijllest extent peMe by law. we do not accept or assumè responsibilty to anyone other than the charitable corYFany and rts members, as a body, for our audrt work, lor this reporL or lor the opinicS we have lomd. Mark urra f¢r and on behalf of Hill Wooldrldge & 107 Hindes Road Harrow Middlèsex HA1 1RU A FCCA (Senio¢ ut¢ry Auditor) . Limlted Oata." 31 August 2Q23 Page 21
THE FEDERATION OF EUROPEAA BIOCHEMICAL SOCIETIES (A Company Limited by Guarante•) STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 310ECEMBER 2022 UnrestrKted funds 2022 Tot¥1 funds 2022 .Total funds 2021 INCOME FROM: Donaltons Charitable actimb.es Investrnenls Other income 660 7,170.000 930,724 56.938 8,044 7,156,235 749,092 12,260 7,170.0 930.n4 S6.936 TOTAL INCOMe 8.164,320 8.164,320 7.925,631 EXPENDITURE ON: Raising funds Charitable activrti8S S31,513 650.091 531.513 6.5S8,091 462,734 3.243,527 TOTAL EXPENDITURE 7.089.604 7.089.604 3,7C6,261 NET INCOME BEFORE NET GAINS ON INVESTMENTS N8t11055Vgain on investments 1.074.716 1.074.716 (10.964.737> 110.964.7371 4.219,370 12.241.697 NET MOVEMENT IN FUNOS {9.890.021) {9.890.0211 16.461.067 RECONCILIATION OF FUNDS: Totsl funds brou9ht fornvard Nel movement in funds 99,178,699 99.178.699 19.890,021) (9I90.021} 2.717,832 18.461.067 TOTAL FUNDS CARRIED FORWARD 89288.678 89,288,878 99,178,699 The Statement of Financial Aetpl.e5 rn¢tyJdes all gain5 and losses rewgntsed in the year. The notes on pages 25 to 44 foffli part olthe5e financral staterrentS. Page22
TrIE FEDERATION OF EURopeAM 0¢EmICAL SOCIETIES IA Company Limited by Guarante•l REGISTEREO NUMBER: 08239097 8ALANCE SHEET AS AT 31 0ECEM8ER 2022 2022 Nole FIXED ASSETS Tangible asse15 Investmenls Scrtial inveslments 12 13 63.507 83.177.926 76.368 92.034,956 72.129 14 83.241.433 92.183.453 CURRENT ASSETS Oeblo Cash at bank and in hand 15 358.895 6,332.321 436,652 7,130,070 6.691.216 7,$66,722 Crethiors". amovnts falling tlue one year 16 1643,9711 1571,4761 NeT CURRENT ASSETS 6.047.245 6.995.246 TOTAL NEW ASSETS B9.288,678 99.178,699 CHARITY FUNOS Unieslri£ted lunds 18 89.288.678 99,178.699 TOTAL FUNDS 89.288.678 99,178.699 The Trustees aCkn0e¢sae their resronsibilthes for mth'n9 With the requirement$ of the Act wlh respect lo accounbng records and preparntw of financts statements. The financial statements have been prepar*J in accordance with thÈ prw$ions appFK•ble io entrties subject tts the Small c(vnpanies regime. The finarK5al statements were approved and authorised lor issue by the Truslees and syned their behalf by: F. Mlehelanptli Trustee Date." 31 August 2023 The notes on pages 25 to 44 fom part of these finar1 statements. Page 23
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES ' IA Company Limited by Gy•r•nteel STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER X22 2022 2021 Note CASH FLOWS FROM OPERATING AcTlEs Net cash us•tl in operating aetivitses 20 307.105 3,725.785 CASH FLOWS FROM INVESTJNG ACTWMES Omdends. Interests and rents from investments Purchase of social investnwnt RepayThent of s181 Investryt Proceeds from sale of investhnts Purchase of invéstmènts 930,724 T49,02 172,1291 72,129 31,539,222 60,940,844 133.646.9291 163,487,550) NET CASH USED IN INVESTING ACTIVITIES 11.104,8541 11,849,743) CHANGE IN CASH AND CASH EQUIVALENTS IN THE YEAR 1797,7491 1,876,042 Cash and cash equNalents at the beginning ofthe )tar 7.130.070 5,254.028 CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR 21 6.332.321 7,130,070 Thè notes on pages 25 to 44 fomi part ofthese financial statem•nts Page 24
THE FEDERATION OF EUROPEAN BIOCHEMICAL SCtIETIES IA Conwany Limiled by Guarant••l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ACCOUNTING POLICIES 1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS The finanual statements have been prepared in accordan¢e vthh the Charibes SORP IFRS 1021- Attounting and Reporbng by Charth"ts." Statement of Recommended Prèetsee applicable to chaTitI'es preparing their accounts in accordance th the Finanual Rerxjrting Standard applicable in the UK and Republi¢ gf Irdand IFRS 1021 leffedNe 1 January 20191. the Financial Reporting Standard applicable in the UK and Republ of Ireland IFRS 1021 and the Charities Act 2011 arnd the Companies Act 2. Assets and Imbilrties a inrtialty recognised at historical ¢951 or transaction value unles5 clherwise ststed in the levant accounb.ng Foly. The Federation of European Biochewical Sccieties Irts the definition of a wbli¢ benerrt enlty a5 defined by FRS 102. There were no swJnificant estimates or judgÈments made by man89èment in preparing these finanual statements. The fvnth.onal and prèsentational llencY is the Euro. 1.2 GOING CThNCERN The Trustees have consmjered the Companys forecasts and projectnS. After making erquires, the Trustees have concluded that there is a reasonable expectation that the Company has adequate resources to conth.nue in operational existence lor the foreseeable future. Therefore, these accounts have been prepared on the going concem basis. There are no material Uncertaint in lab.On to tsng concem. 13 INCOME AJI income is CogniSed Ore the Company has entitment to thè ineomt, it is probablè Ihat thè income wll be received and the arrw)unt of ineomè receNable ean be measured reliab. Income from rorotties is rewnised in kne %wth the period to which it reles. In¢grre from grants and donatn$ are recognvd the Company has been nots"fi8d in Wrng of both the amount and 5etU•ment date. In the event that a grant or donatKJn is sybiecl to condrtions that require a level ol perfoimance before the Company is entrtsed to the lunds, the Inco Is delerred and not recogni5eJ unbl those ConditnS are ftjlly me( or the fulhllment ol those condrtions is whdly vithin thè control ol th• Company and rt is probable that those conditsons wll be lulfilled in the reporting peiiod. Investmènt in¢ome 15 COgnIsed in the period in which the Company coMeS $nte lo the incoTr*. Interest on funds held on deposrt is included when reNable and the amount can be measLsrg0 reliably by Ihe Company. this is nommlly upon nobficatron of the interest pahd or payable by the Bank. other income is reeogni5ed in the Perh in wthich it is receivable and to the exient the goods have been provided or on coMpl"0n ol the service. Page 25
THE FEDERATION OF EUROPEPJ4 810CHEMICAL SIXIETIES IA Company Limit•d ty Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER XJ22 ACCOUNTING POUCIES ICONnNUED) 1A EXPENDITURE Expenditure is Tecognised oncè theie ts a legal oi eonstructivè ob19atTr to transfer economic b?nefit to a third paty. rt 15 probable that a transfer of economic benefit5 wll r•quir•d In settlement and the armunt ofthe obh3a1Th can be nasured rellay. ExpÈndrture on raing lunds indude5 all èxpèndrture incurred by the Company to ratse funds lor its charitable purposes and Includes costs of all fundratsing actsvitS events and non<harit8ble Iradin9. ThLS comprr5e5 investment management fees. Expendrture on charrtable actmties is incurred on (Jirectly undertaking the actNities which further the Compan1$ objectNes. a$ well as any assoaated support ¢osts. Alloeatth) of costs ts based On a¢ANtywhieh has drNen the revant cost. Grants p8yablÈ are charged in the yearwhen the offer made except In those cases where the offer 15 conditional. such grants being recognised as expenditure when the conditions attaching are fu111ed Grants offered 5utsject to condittons which have not been at the year eTrd are noted as ¢0mmint. but not accrued as expendf(ure. Governance costs are those incurred in connection wth administration of the Coryjany and ¢omplFance wrth constiiutional and statualory requirements. 1.5 FOREIGN CURRENCIES Monetary assets and liabilitS denominated in foreign curr¢no¥s are translatèd into uros at rates of exchange ruling at the reporting date Transactions in fo[en curren¢ies are translated inlo eums at the rale ruling on the date of the transaeb"on. Exchanp gains and b)$ses are recognK%ed in the Statement of Financial Activities. 1.6 TAXATION Thè Company ts con5idereil to pass the tests set out in Paragraph 1 Sch•dulÈ 6 of the Financ• Act 2010 and therèfore rt meets the definrt¢on of a charr(able company lor UK corwfatiort lax purposes. Accordingly, the Company is potentially exempt from taxation in respèet of incgrne or capital 9ains receNed wpthin eateggries covered by Chapter 3 Part 11 of thè Corporthon Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992. to the extent that such incoff* or gains are applied exdu5Nely to charitsble purposes. 1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION Tangible fixed assets are InallY recogDi5ed at cost After recognition. under the cost rmdel, lan9iblè red a$sèts are measured at cost less accumulated depcratIOn and any accumulated impairment losses. All costs incurred to bring a tsngible ftged asset into rts intended working condf(ion should be included In the measurement of cost Page 26
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Conwny Limited by Guaranteel NOTES TO THE FINANCIPL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ACCOUNTING POUCIES (CONTINUED) 1.7 TANGIBLE FIXED ASSETS OEPRECIATION {CONTINUEO) Depr•erdtion is eharged so as to aifoeat• the cost of tsn9Ib fLxed assets less their re%dual valuè overtheir e5b"maled usefvl INes. D•prnuation i5 provided on the fo"n9 base5." Leasehobj inwr0mefits Fixtu$ and fittings Computer equiprynt and websrte overthe life of the ka5e 15% on rèducing balance 25% on reducing balance 1M INVESTMENTS Fixed asset investments are a fom of ffinancial instrument and are initially recogntsed at their IransactR)n cost and subsequenuy measured at fair value at the 8alan¢e Sheet dale. unless the value ¢annol be measured reliabty in which case rt is measured at cost less impairment. Investment gain5 and losses. whetrer rea115e(l or unrealt5ed. are combined and presented as 'GaInSLoSsesI on investments, in the Ststement of F+na[la1 ActsVeS. Investments hekl as fLxed assets are shown at ¢o$l less prtiviston for inwaim)ent 1.9 SOCIAL INVESTMENTS Programme related investmènt5 are held at lair value if tht5 be measured reliably. If lair valu Cannot be measured reliabty. they are held at eost le$$ iryairnnt. 1.10 DEBTORS Trade and other debtors are recegnised at the settlement amount after any trade discount offered. Prepayments are valued at the anx)unt prèpaid net of any trade diseounts due 1.11 CASH AT BANK AND IN HAND Cash at bank ¥nd in hand includes cash and short-tenn l]uid investments with a short nwturty of three rrrfjnlhs or $S from the date of aCquis.0n or opening ofthe dep05rt gr simil¥ account 1.12 LIABILlEs AND PROVISIONS Liabiliti'es are rec(Jgnised when there is an 0b1vJatn at the Bala Sheet date as a result of a past even( rt is probable that a transfer ol economic benefit wll be required in settlement. and the amount of the settlement can te esb"mated reliably. ab11.e5 are re¢ggnised at the amgunt that the Company antiapates it wll pay to settle the debt or thè amunt rt has rèceNed as aijvanced Paftts for the goods or seNice5 it musl provide. Provi%n5 ale nasured at Ihe best esb"mat¢ olthe arrK)unt$ r¢quir¢d to setue the obli9ation. Whare the effed of the time value of money is material. thè provision is basèd an the present value ol those amounts. discounted at the pre-tax discount rate that reflects the risks specific to the liabilty. The unwnding of the discount is reco9nised in the Stslement of Finan¢ial ActNity"es as a finance cost. Page 27
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES . (A Conwny Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2022 ACCOUNTING POLICIES (CONTINUED) 1.13 FINANCIAL INSTRUMENTS The Corrpany onty has financral assets and finanoal liabilitEs of a kind that qualify as bas financial instruments. Basic finanual inslrunEnts are initially recognised at transaction value and 5ubsequenly measured at their 5etllerrenl value with the exception of bank loans whh are subsequently measured at anKJrtised cost using Ihe effeth.ve intèrest mèthod. 1.14 OPERATING LEASES Ranta15 paid under opèratin9 ases are charged lo the Ststement ol Financial Adiwb"e$ on a straight4ine basis tiver the lease term. 1.15 PENSIONS The Company operates a defmed c)ntrtJution pension scherrE and the pension charge represents the amounts pardble by the Company to the fund in respect of th8 year. 1.16 FUND ACCOUNTING General funds are unrestitted funds Ythh art ayéilable for tss• at th• derlon of the Trustees tn furtheran of the 9eneral objectNes of the Company and whKh have not teen designated for other purposes. Rèstri¢ted funds ao fvnds lch are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Conwany for particuLar purposes. The costs of raising and admini5teiing svch fvnds are charged against the Spec fund. The aim and use of each restricted fund set out in the notes to the financMI statements_ CRITICAL ACCOUN71NG ESTIMATes ARES OF JUDGEMENT Estimates and judgments are continuall evalu*ed and are based on hfOral experience and other factors. The resutting accounbng estim es and assumptions wll. by definrth)n seldom equal the relatèd actsal resuts. There are no esbmates and assumpbons that have a significant nsk of causing a materk81 adjustment to the ¢arryng amounts of assets and lbil&S wthin the nèxt finan31 ytar. INCOME FROM DONATIONS Unrestricted fund$ 2022 Total funds 2022 Subscriptions receNable 6,e60 6.660 Page 28
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limrted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2022 INCOME FROM OONATIONS {CONTINUEDI Unrestricted funds 2021 Total runds 2021 Subsuipts'ons reeeivab 8.044 8.044 INCOME FROM CHAJIITABLE ACTIVITIES UnrestrKted funds 2022 Totsl funds 2022 Royalbes rec•Nae 7.170,000 7,170.000 Unrestricted fvnds 2021 Total funds 2021 Royaw r¢¢eivgNe 7.156,235 7,1S8,23S INVESTMENT INCOME Unrestricted funds 2022 Total funds 2022 Franked investment inL*me- di¥idends Interest received 608.294 322.430 322,420 TOTAL 2022 930,724 930,724 Page 29
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIEfiES Company Lknileql by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOEO 31 DECEMBER 2022 INVESTMENT INCOME IcoimNUED) unre5tn.cted funds 2021 Total lunds 2021 Franked investnnI incowr- dIdendS Intèrnst received 604,865 144,227 604,865 144,227 TOTAL 2021 749,092 749,OY2 Investment incoTr trom UK invéstment assets wa5 f198.24412021." É131,6811. Investment income from investnnt assets outside the UK was 32,460[2021." É817,4111. OTHER INCOMING RESOURCES Unrestricted funds 2022 Total funds 2022 other income 56,936 56.936 her incomng resour compiise recharges on edrtjal actNrts. Unrestricted funds 2021 Total funds 2021 ¢Jh¢r incom¥ 11260 12,260 INVESTMENT MANAGEMENT COSTS Unrestricted funds 2022 Totsl furKIs 2022 Portfolio wonagement 531,513 531,513 Page 30
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) NOTES TO THE FINANCINL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 INVESTMENT MANAGEMENT COSTS (CoriNUED) J.P. Morgan PTNate Bank. the Companls investment manager. holds a charge over the Cornpany'5 cash and Investn*nts rt manages on behalf ofthe Company. Unroslrictéd funds 2021 Total fund$ 2021 Portr10 rrranagement 462,734 462.734 IALYSIS OF EXPENDrruRE 8Y ACTIVITIES Grant funding of Support and activities governanc• {note 91 2022 £tivities undertaken directly 2022 Total funds 2022 2022 Journals congS$ Fellowship5 Advanced courses Crthef 363.445 233,W23 Z336.428 379.866 219.575 264.795 916,330 2.699,873 864,148 1,113.318 771.243 1.109,509 250,459 893.743 506.448 86,858 1C6.321 TOTAL 2022 703,589 1.737,508 4. 116.994 6,$58,091 Page 31
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Gu¥anteel NOTES TO ThE FINANC STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF EXpENDuRE BY ACTIVITIES (CONTINUED Grant funding of Support and activities governance Inote 91 costs 2021 2021 undertaken directy 21r21 Total funds 2021 Journals Congress Fellowships Advanod courses Other 302.688 110.646 1.129.023 132.877 74.963 106.860 231.384 1,431,711 440.321 891.795 203,992 275.7( 1.798 816,832 97,132 34,653 9,671 TOTAL 2021 423,005 1,145.415 1,675.107 3,243,527 ANALYSIS OF DIRECT COSTS Total fund$ 2022 Joumal$ CongrÈss 2022 2022 othèr 2022 Edrtonal feès and wènse5 Women in science events Education, fellowship and advanced covrses commrttte èvènts 363.445 363.44S 11,554 11.554 7,562 38.841 4.B68 5.505 46.403 4,868 5.505 79.465 130,202 57.107 5.040 Science and Society events National I*¢tu expenses FEBS Congress FEBS Young Scientists fonjm congr•ss WGI part1patIon events Spinzl scheme 79,465 130.202 57.107 5,040 TOTAL 2022 363.445 233.823 106,321 703.589 Page 32
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETES IA Con4)any Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2022 ANALYSIS OF EXPENDITURE BY ACTIVITIES ICONnNUED) ANALYSIS OF OIRECT COSTS I¢<tinUeI Total fund5 2021 Journals Congiè$s 2021 Other 2021 Edrtorial fees aThJ &xpen*5 Womén in scienc• events Education, fellowship and advanced courses committee events Sfyon¢¢ ¥nd Sothèty events Nats"onal lecture 8xpense5 FEBS Con9ress FEBS Young SnI15ts forum congress WGI Participation ¢vents Spinzl sch•me 302.686 10,014 10.014 1.500 2,250 443 67,085 30.422 5.478 3,12S 2.250 443 67.085 30.422 5.478 3.125 TOTAL 2021 302.688 110.646 9.671 423.005 ANALYSIS OF SUPPORT COSTS Advanced courses 2022 Journals Congress Fellowships 2022 2022 2022 Editorial feès and expens¢$ HR and communications Financè and gov¢manr IT & website Education, felloliP and advanced courses conynrttee events 1.123.287 7.948 90.286 6.246 61.6C(I 90.286 6,248 7,948 34.395 6,248 13.910 77.388 6,248 60,118 110,866 .383 110,866 Foreign exchange losses 1.108.e61 221.732 TOTAL 2022 2.336.428 379.866 219.57S 264,795 Page 33
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Comp•ny Linyted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF EXPENDITURE BY ACTIVITIES ICONThUED) ANALYSIS OF SUPPORT COSTS Icontlnued) Total funds 2022 Other 2022 Edrtoiial fees aThJ expenses HR and CommunlI0nS 1.123,287 198,710 429,936 31,238 116,501 2.217,322 107,304 137,581 6,248 Finance artd yovem8nce IT & b9rttr EducatK)n. fellowship and advaneèd etyjrsès eorrmttee events Foreign exchange losses 665,197 TOTAL 2022 916,330 4,116,994 Advanced courses 2021 Jtyjmals 2021 ¢ongrè$$ F*llowships 2021 2021 Edrtorial fees and Èxpèft5e5 HR and communutions Finance and govemance Women in science events Education. frllowship and advanced couises cornm¢¢ events National l•cture expenses Foreign exchange lossés 1,014,768 7.324 38,438 23.849 56.762 38,438 23.849 7,323 14,643 11,924 12.816 32.947 11,924 34.159 4.083 2.831 42,259 4,083 2,831 16.333 28,311 8,186 TOTAL 2021 1.129.023 132.877 74.3 1C6,860 Page 34
THE FEOERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Gu4¥4nt¢¢ NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF EXPENOITURE BY ACTIVITIES (CONTINUED) ANALYS15 OF SUPPORT COSTS {contihtsedl Total funds 2021 other 2021 Edrtorial fees and expenses HR and communl)n$ Finance and govemance Women in science events EdUCatn. felbwship and advanced courses ¢orrnirtteè evants National lecture expense5 Foreign exchange knsses 1,014,768 183,102 183,038 79.496 76,418 81,663 ,622 98,877 58,572 7,950 48,998 16,987 TOTAL 2021 231,384 1.675.107 ANALYSIS OF GRANTS Grants to Instiiutbons 2022 Grants to Indivwluals 2022 Total funds 2022 ¢ngre55 Fellowships Advanced courses Other 89,426 181.033 893,743 73.277 38,209 250,459 893.743 506,448 86,858 433,171 48,649 TOTAL 2022 571,246 1.166.262 1.737,508 Page 35
THE FEOERATION OF EUROPEAA BIOCHEMICAL SOCIETIES IA CompaThy Limited by Guarantoè) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF GRANTS ICONTINUEDI Grants to InStrtutnS Grants to IndNiduals 2021 Total funds 2021 Congress Fell¢)wship5 Advancd urSe$ other 146.125 50,673 816,832 10.019 9,653 19S,798 816,832 97,132 34.653 87.113 25.000 TOTAL 2021 258,238 887,177 1.145,415 The Company hos ffde the following materwl grants to in$kntutions during th• year. 3)22 2021 NAME OF INSTITUTION Advaneed courses 433,171 89,428 3,290 40.359 s,000 87,113 146, 125 FE8S Congress Grant Grantslsponsor5hip to other Orglsa.0nCnIertnCes FEBS3+ Grant Imnce for Bion*dical Re58a(ch Grant 20.000 s.o $71,248 258,238 S71.246 258.238 10. AUOITORS. REMUNERATION 2022 2021 Fees payable to thè Companfs audrtor for the audf( ofthe Corryanys annual accounts 20.650 20,226 Page 36
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETES {A Conwny Limited by Guarantee) NOTES TO THE FINANCIPL STATEMENTS FOR THEYEAR ENDEO 31 DECEMBER 2022 11. STAFF COSTS. KEY MANAGEMENT PERs(NELD TRIJSTEES. REMUNERATION AND EXPENSES As restated 2021 )22 Wa9ès and salariès Social securty costs other pension costs 963.723 155,975 99,635 925,791 140.1 91,909 1.219.333 1,157,896 During the year, Paents arnth9 to É3.966 Ere made to one èmF4oyee in r&set ol voluntsry redundancy. The avero9e numbef of persons ernpkjyed bythe Company during the year was as follows.. 2022 2021 Publieations Icambndge, UK) pUbltionS (Heidelberg. Gemwnyl Publications (Bareelona, Spain) Treasury Central adrnin 18 One employee recewed remUneratn faling vth"n the band f70,(KK) lo E19.939. The key management personnel of Ihe Coryany comprises the Tnjstees. The Trustees all their "me and expertise without any kind of remunerab.on or other benefit in kind with the excepb'on of the folbw'ng Twstees who provided s*Nces to the Company during the year. Page 37
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limtted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENOED 31 DECEM8ER 2022 2022 2021 M De La Rtssa (Edrtorial s¢rM¢esl l Diaz Mof•no IEdrtorial s•rvie•sl C Arraiano (Editorial services) B Vértessy (Edrtorial semcesl 25.266 585 25,216 985 385 26.211 26,$86 These services are in accordance Ihe Company$ 9o¥¢ming document and in accordance with sèctions 185 to 188 of the Chafth"è5 Ad 2011. During the year, 12 12021". 61 Trustees ree¢Ned reimbur5ernnt of expenses or had $xpen$e$ paid directty to a third paty on their behawtotalling Q5.64512021". Q,3971. Other personnel costs Due to the geographi¢01 spreasj of the Cory¥anls actNikne5, some stsffing requirelnents are fulfilled by independent parb'es and freelancers. Detsils of cost and numb•r ol per50nnel eontraeted in this manner are detailed below 2022 2021 cOpenhan Journals Administrator Fellowship Commrttee Administrator Advanced Courses Comrttee Adnynistrator 20.010 26,000 23,549 28,0(NJ 26.872 54.872 69,559 The average number of other such personnel linduding part4ine person1) engaged by lh* Company during the penod was 0$ folbws". 2022 2021 Copenhagen Journals Adminislrator Fellowship Commitlee Administrator Advanced Courses Conwnittee Adrrynistrator Page 38
THE FEDERATIi)N OF EUROPEAN BIOCHEMICAL slET1£s (A Company Limit•d by Guarantee) NOTES TO THE FINANC STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 12. TANGIBLE FIXEDASSETS Computer Leasehold Fixtures and equipment Improven¢S fittings and website Total COST At 1 January2022 S9,1 12.390 104.338 176,4109 At 31 Oecember 2022 S9,1 12.390 104.338 176,409 DEPRECIATION At 1 January 2022 Charge for the year 13,217 4.198 82.626 5.428 1(Kl,041 12,861 At 31 Dee8mber 2022 19.421 88,054 112.902 NET BOOK VALUE At 31 Dwmber 2022 6.963 16.284 63.507 At 31 Oecember 2ff21 46,464 8,1¥2 21,712 76,368 13. FIXED ASSET INVESTMENTS Llsted Cash held * broker Total VALUATION At 1 J8nuary 2022 91A18,846 Ad(htigns 33,261,786 Disposals (proceèds Q1.$39.222," re*ised loss £l.803.2081 133J42.4301 Revaluations 19.161.529) Cash rro)vement 226,110 92,034.956 33.261.786 133,342,430) 19.161.529) 38S,143 385,143 AT 31 DECEMBER 2022 82,566.673 611.253 83,1TI.928 Page 39
THE FEDERATION OF EUROPEAN 810CHEMICAL SOCIETIES IA Company Linwted by Guarantee) NOTES TO THE FINANcL STATEMENTS FOR THE YEAR ENDED310ECEMBER 2022 13. FIXED ASSET INVESTMENTS {CONTINUED) The market value of investment asset5 in the UK É10,282.69312021". É16,134.9701. The market value of investffnt assets outside the UK is 2.283.980[202l." Q5.673.8761. FEBS seeks to pThJuce the besl financial return wthin an acceptable level of risk. The investments are to enable FEBS to fvnd its activrties in the long4erm. The returns on investment are to provide funding of charrtable aCtrtIeS and to increase the syze of the inve5tnnt fund in the next 7- 8 years. The aim 15 to increase the sEe of the investrrent fund to Pro¥e hMJher income sn the fijture to offset any potential reduction in income from royatties. The InveSnt objeclNe is to generate a retum of HICP plu5 3 5%, over the long term, after expènses. HICP the Harmonised Index of ConsurrEr Pri$ is lo be used as a measure. This should allow FEBS to at least maintain the real value of the assets, whilst funding annual expendrture over tirne. FEBS has a tsrget level of investrrt that wll cover any shortr811 from publicatn5 incorre. FEBS uses a lotsl retum investment strategy The tot81 net gains on investments as pef the statent of Financial Acbvrties comprises Tealised bsses of É1.803,208 and unfealised losses ofE9.161.529. 14. SOCIAL INvesTMENTS Programn related inY•stments Total COST At 1 January 2022 Redewion 72.129 172.1291 72,129 172,1291 The social investrnent represented a non-interest-bearing loan to fvnd the Bi¢xhemical Global Surnmf(. vthich look place in $bon beh¥een 9 and 14 Juty 2022. Thè loan was repaid during the year. 15. DEBTORS 2022 2021 Trade dèbtors Other debtors Prepaym¢n15 and accrued incon 146,393 61154 150,348 24.761 36,079 375,812 358,895 436,652 Page 40
THE FEDERATION OF EUROPEAN BIOCHEMICAL SIXIETIES (A Company Llmi¢ed by Gu•r•ntsel NOTES TO THE FINANCI STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 16. CREDITORS.. AMOUNTS FALLING OUE WH1N ONE YEAR 2022 2021 Trade cieditors otherta¥ab"on and social security other uedrtors Accruals and dèleffed incon 212,873 349.499 2.704 78.89S 121,864 363.952 405 85,255 643.971 571.476 17. PRIOR YEAR AOJUSTMENTS It has been enty'fied that staff costs relab.ng to employees working in Germany and Spain had been omrttèd Irom the"staff costs disclosure (note 111. The e¢t ol includin9 these costs is an increase in wages and salaries. socnl security costs and other penOn costs of 88,147. É85,013 and É12.092. re5pe¢lwely. The impad of this omi$sn is confinet1 to note 11 staff costs. thè Statement of Financial Athities and Balance Sheet as wesentetj in the prior-year accounts a unaftected. Page41
THE FEDERATION OF EUROPEAN BIOCHEMICAL"SOCIETIES IA Company Limited by Guaranteè) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDEO 31 DECEMBER 2022 18. STATEMENT OF FUNDS STATEMENT OF FUNDS- CURRENT YEAR 8alance at 31 Gainsl Dernber ILossesl 2022 Balance at I January Incomè Expenditure UNRESTRICTED FUNDS General Funtjs 99.178,699 8.184J20 17.089.604) {10.964.7371 89.288,678 STATEMENT OF FUNDS - PRIOR.YEAR Balancè at 31 December 2021 8alance at 1 January 2021 Gainsl L055esl Ineome Expendrture UNRESTRICTEO FUNDS General Funds 82.717.632 7.925.631 13.7C6.2811 12.241,697 99,178.699 19. ANALYSIS OF NET ASSETS BETWEEN FUNOS ANALYSIS OF NET ASSETS BETWEEN FUNOS- CURRENT YEAR UhtriCted funds 2022 Total fvnds 2022 Tangible fixed assets Fixed asset invèstments Current assets credrtO due within one year 63.507 63,507 83.177.928 83.177,926 6.691.216 6,691.216 1643,9711 1643.971) TOTAL 89.288.678 89.288.678 Page 42
THE FEDERATION OF EUROPEAN 810CHEMICAL SOCIETIES IA Coftyany Limit•d by Guar*nteÈ) NOTES TO THE FINANCIALSTATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2022 19. ANALYSIS OF NET ASSETS BETWEEN FUNDS (CONTINUED) LYSIS OF NET ASSETS BETWEEN FUNOS- PRIOR YEAR Unrestricted funds 2021 Total funds 2021 Tangible fixed assets FLxe¢J asset investments Sooal investrnents Currant assets Credrtors due wthin one year 76,368 76,368 . 92,034,956 92.034,956 72,129 72,129 7,5fj6,722 7.,722 1571,4761 1571,4761 TOTAL 99,178,699 99,178,699 20. RECONCILJATK>N OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES JJ22 2021 Net 18xpendrtUrèlne•ft for thè year (as per Staterrent of Financial Acbvrties) 19,8W.021} 16,461.C67 ADJUSTMENTS FOR: Depreciatr'on charges Lossesllgainsl on investments ONidends. inttrrests and rents frryn estrntS Decrease in debtors Increase in credr(ors 12,861 14,885 10,964.737 112.241.697 1930.7241 1749,0921 77.7S7 118,242 71495 122,380 NET ¢$H (USED INVPROVIDED BY OPERATING ACTIVITIES 307,105 3,725,785 21. ANALYSIS OF CASH AND CASH EQUIVALENTS 2022 2021 Cash mi hand 8.332.321 7, 130,070 TOTAL CASH CL8H EQUIVALENTS 6,332,321 7,130.070 Page 43
THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Gu•ranteel NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022 ANALYSIS OF CHANGES IN NET OE8T At31 Dtetmber 2022 January 2022 cash Ilows Cash at bank and in hand 7.130,070 1797.7491 6,332.321 7.130.070 1797.7491 6.332.321 23. OPERATING LEASE COMMITMENTS At 31 December 2022 the Company had commthènts tts make luturè minimum lease payments undèr n0n-c8nce1b1e operating aSeS as follo.. 2022 2021 Not later than 1 year Later ihan l year and not later than 5 year5 S5,969 13.992 58,967 73,709 69.961 132.676 24. RELATEO PARTY TRANSACTIONS The Corrpany has not entered into any related paty transaction tluring the year. nor a Ihere any outstsnding baknces owng beN¥een rÈL4ted Pa"•$ and the Company at 31 December 2022. Page 44
APPENDIX 1 Constituent Socie Armth• Address Association of Armenian Biochemists IAABI H. Buniatin Inst. of Biochemistry, National Academy of Sciences. Sli Paruyf Sevak Str. Yerevan 375D14 Republic of Armenia www.aab.sci.am Osterreichische Gesellschaft fvr Molekulare Biowissenschaften und Biotechnologie IOGM8TI Ma0X. VBC. Helmut-Qualtingerfjasse 2. Stiege 02, EG L.01. 1030 Wien Austria www.oe mbt.at BefaNs- IAssociorel The Belarusian Soctety of Biochemists and Molecular 8iolo@ists18S8M81, Institute of Biochemistry of BiologicolW Acttve Compounds, Nattonal Arademy of Scienw, 50 Lenin Komosornol 8oulevard, 230030 Grodno, Belaws. Société 8èlge de B1hlmIe et de Biologie Moleculaire IBMBI, Nanobody Lab, Dept. of Biochemistry, Ghent Univeisity. Altert Baertsoenkaai 3 gX(J Ghent 8el8ium www.bioth mist .be Èdglum 805nla and Her2e8oMna Association of Biochemists and Molecular Biologists in Bosnia and Herzegovina IABMB in 8&HI Faculty of Medicine. University of Sarajevo, tekalula . 71(U) Sarajevo, Bosnia and Herze8offlna www.ubmbubih.net 8ulgarian Biwhemical. Biophysical and Molecular Biology Sooety IBBMBSI, Institute of Btophysic5 and 8iomedical En8ineerin& Bulgarian Academy of Sciences. Acad. G. 8onchev st.bl 21. Sofia 1113. 8ulgaria www.old.uslFb or sections.htm Croatian Society of Biochemistry and Molecular Biology IHDBMBI. Ksaverska cests 2. HR-ICKJOO Zagreb Croatia www.hdbmb.hr OLO<-Sooecy of &0108ical Sciences in Cyprus l¥io(-SBSCyl. Department of Biological Scierices, Univer51ty of Cypius. l University Avenue. Aglandjia 2109. Nicosia, Cyprus htt Ciech &iciety lor &'ochemistry and Molecular Biology ItSBM81. Kladen5ka 48, CZ-16 000 Plague 6 Czech Republic www.c5bmb.ci Danish Biochemical Society (Dansk Biokemsk Foreningl. Unit of Cell Stress and SurvNal. Center for Autopha8y, Recycling and Disease. Danish Cancer ScKiety Research Center. Strarbdboulevarden 49, OK 21CM) Copenha en O. Denmark www.knoketri.o¥ en Estonian 8iochemical S(Kiety IEBSI. Tallinn Uruversity of TeChl08v. Ehitajate tee 5. 19086 Tallinn, Estonia www.biokeemiaselts.ee Societas Biochimica. Biophysica et Microbio108ica FennIae(8bio Society). University of Helsinki, Haartmaninkatu 8, He15inki Finland www.biobio.or Société Francaise de 8iochimie et Biologie Moléculaire ISFBeMI. IBMC, 15 Rue René Descartes. 67084 Strasbour Cedex, France www.slbbm_fr Assotiation of Georgian Bio¢heffli5ts IAGBI. Institute of Chemical 8iotyy, Ilia State VnNersity. 315 K.Cholokashvili Av.. Tbilisi 0162. Geor Gesellschaft fur Biochemie und MolekularbiolL%ie G8M e.V. IGBMI. Morfelder Landstr. 125 0-60598 Frankfurt/Main, Germany www. bmnI1ne.de Hellenic Society of Biochemistry and Molecular IHSBM8111 Soufliou Stfeet. Athens IIS 27 Greece www.eebmb. Hun8arian Biochemical Society Imagyar Biokémiai Egyesulei- MBKEI. Institute of Enzymology. Research Center for Natural Sciences, Hungarian Academy of kiences. Magyar tudosok korutja 2. H-1117 Budapest, Hungary www.mbke Israel Society lor Biochemistry and Molecular Biology IISBMBI. Dept. of Biological Chemistry, The Alexander Silberman Institute of Lrfe Science. The Hebrew UnNersity of Jèrusalem. Givat Rèrn Campus, Jerusalem 91904, Israel www.weizmann.ac i isbmb Bul8arla Croatla C2ech Aèpublk Denrnark Estonla Flnland France Georw Gennany Hury l$rael Societa Italiana di 8iochimica e Biolo8ia Molecolare ISIBI. Dip. to di Scienze Biochimie 'A. Rossi Fanelli.. Sapienza Universita di Roma. P. le Aldo Moro S, CK)185 Roma. Ita www.biochimica.i Latvian Biochemical Society ILa851. Latvian Biomedical Research and Study Centre, Ratsupites Street I, LV 1067 Riga. Latvia Lithuanian Biochemical Society ILBDI. Sauletekio al_ 7. LT-10223 Vilnius. Lithuania www.biochemist .11 iat¥4a Lbthuanla
Moldova (Associotej Moldovan Society of 6iochemistry and Molecular Biolo IMSBMBI. Institute of Genetics. Phy5io108y and Protection of Plants. Academy of Sciences of Moldova, 20 Padurii Str.. Chisinau. 2002-MO Moldova Moroccan Society of Biochemisiry and Molecular Biology1SMB8MI, Ha55an 11 University of Casablanca, Laboratory of Sciences. Faculty of sciees and Techniques. 8.P 146 Quartier Yasmina, Mohammedta, Morocco The Netherlands Society for 8icKhemistry and Moleculaf Biology INVBMBI. NMR Group. Dept. of Chernistry, Utrecht LJnlverty. Padualaan 12. 3584 CH Utrecht. The Netherlands www.kncv nl nvbmb Norwegian 8iochemical Society INBSI. NTNU, Fakultet for medisin og helsewtenskap. 7491 Trondheiffl. Norway www.biok"emisk.com Polish Biochemital Society IPT Biochl. Nencki Institute of Experimental Biology, 3 Pasteur str. 02-093 Warsaw Poland www. tbioch.edts. Portuguese Biochemistry Society ISP81. Faculty of Pharmacy. University of Lisbon. Av. Prof. Gama Pinto. 1649-003 Lisboa, Portu al www.s Romanian Society of Biochemistry and Molecular Bk)logy IRS8hABI. Institute of Biochemistry, Splaiul Independentei 296, sect. 6, 06Th)31 Bucharest. Romania www.srbbm.biochim.ro National Commitiee of 8iochemist5 anij Moleculaf Biologists INCBMBI Shemyakin-ovchinnikov Institute of Bioorgansc Chetni5try. RAS. Ul. Miklukh¢FN4aklaya, 16110. 117997 Moscow. Russia www.rusbiochem.or Serbian 8iochemical Society ISBSI, Depanment of 8iochemisiry. Faculty of Chemistry. University of Bel rade. Studentski tr 16. IIWO Bel rade Serbia www.bds.or rs en home.html Slovak Society for Biochemistry and Molecular 8iology ISS8M81, Dept. of Mo)lecular Biolo&w, Faculty of Science. Chades Llniversity In Bratilava, Ilkowcova 6, 842 15 Bratislava Slovak Republic www.ssbmb.sk Slovenian Biochemical Society ISBDI. Universtty of Ljubljana. Faculty of Medicine, Vrazov trg 2, Sl- I(KK) L ublj3na. Slovenia www.5txl.51 Sociedad Espafiola de Bioquimica y BiologTrca Molecular ISEBBMI. CIKSIC. clRamiro de Maetzu, 9 E-28(MD Madrid, S ain www.5ebbm es Svenska Kemisamfundet (The Swedish CheMal Society.. SFB8MI, Svenska KemisamfvndeL Nafingslwets hus. Storeatan 19, SE-114 51 Stockholm. Sweden htt kemisamfundet.se sektioner biokemi-biof sik-oth-Tnolek larbiolo Life Sciences Switzerland ILS21. Swiss Society foi Moleculor and Cellular Biosciences. MCB section of L52. Institute of Cell Biolo Universrty of Bern. Switzerland www.152.ch TheTunisian Association of Biological Science5 IAT5B- A550Clation funisienne des Sciences 8iologiques-l Dep Biolo8ie- INSAT. Université de Carthage. 8P 676- Centre Urbain Nord, ID80 Tunis cedex. Tuni5ie Www.atsb4o.0r Turkish 8iochemical Society (TBSI, Ege University. Faculty of Medicine. Oept. of Biochemistry. 12mir, Turkey www.turkb" okim rne Ukrainian 8iochemical Society IUBSI, Palladin Institute of 8iochernistry. 9 Leoniovicha SL 01601 Kiev-30 Ukraine www biochemist .or .u Index. en The 8iochemical Society, l Naoroji Si. London. WCIX OGB. UK www.biochemisi M1£0 {Associotel Netherlands Norway Pojand Portwl manl Serbla Slovakja ovenla Spaln Sweden SwStterland Tuni51a {As50CiOte} Torkl Uknlne united Kln om .or FEBS had 39 Constituent Socties in 2022, comprising 35 Member Societies and 4 Associate Member Societies.
APPENDIX 2 ."i. Sulxrl 120 C l A$souati clArNtnian BAfftmi5ts 30. 2 Av$rrfiAssQCtffj cfmdecular LiffeScrttsaftd etloGMBT) 626 156.50 3 Sociéré Bellede ts1et de Biolcye WwJtsire 125.( 4 ABM8 in 805nia and 1rzegLoa 10) c 25.0) 5 bulyrian S0(ietyfw Bmxhemisrry. mecU èK4oy 6 &oati sor¢1 BK)theffM5tryand Mc4ecu Bvj 514 C j28.gj 7 Sooetyof 8iob28iC31 S¢erKe56ThCvkYus 120 8 Czeth Soaetyftr BK) 620 s.tx) 9 so)etyf gxhemtsbryand 8b)k• 95.Dl IQ EstorMaTh Stixhernlc Souety 27.50 11 Suca5 BA)CheMa. Bl['(ae¢ Fenrriae 515 128.75 12 &xété F¢an(de ewxhin etde 8eAre ISFBBMI 325.co 13 A$sall0 ofGeu8ilh) &therSt5 14 Gesellxhèft fur und e.V. 20.75 1870 717.$0 15 HelrM¢5ocietyof eAstryand Mdecul¥ &okfflf IS Hungari 8kithemK knety 17 15rad Soaetyfot BiothEmLttryandMdeOJr Blob 200. 41 C 10.25 18 rt31ian Soaetyof B?themi5tryand B i.(ts) 250.( 19 L3tw3n BI0thernK Sotiety 20 tilhuan1 eK)¢hemK4 Socty 265 C Zl NederlèndseVerenIgtngvr Trthyttdaire B"¢ I,C67 C 266.75 22 P+arwlaTr Stiuety 75.co 23 Pof15h èty?chemd 1.014 253.so 24 P¢nugue5e 810chw¥l 350 87.50 25 letate¥ Rom3na de BMies1 Ie¢uLa 26 Serban BCheMic& Sottty 45. 27 Ycwak Sooetyfw 9Kxhernwryd MokniLv &0 55.f 28 SIr¥eni aerr¥Ol &x5E 220 5S.C 29 EspaTrYède Bwu¥nthy BK•ica Mdetul¥ 2.911 C 727.75 30 Swedishsooety 8thernry. bwtrrysK5)d Mdetul¥ 426 106.9) 31 Ule SCIee$SwIt1Iand ILS21 947 236.75 32 Turknsh &"¢thKè1ety LSO.ts) 33 &lKhernlS0tsety 6,137 C L534.25 34 Ukiaihiafi 81th¢m S(Kty 170.CY) Tolal 25,836 É 6,459.LXJ OCIATE MEMBERS . *4..- Moldwan 5ooetyot BCheft$tryano Mde¢ukr 8h?108y IMSOMOI Morto¢<an 5wetyof BemiStry8rtdMdé¢UI unlASS0CiaE of al811&rKes IATSBI
COMPOStTK)N OFTrE FEBSCOMMfThEESAND WORKING GROUPS D THE GEcRI>HlCAL DlSfRIBulloN OFTHE MEMBERS APPENDIX 3 janry L 2022- Deeefflber31, 2022 twmer4ts1 pogyonfor {rldecii tostart l.L2023 E<ECWIVE COMMrrrEE ett£d in Ending Plotr ialdler thalrperson (y120191 010121 .3112 22 0120 311220 Janko Kc Mc&thalr onllnel20201 010121 .3112 22 Vadav Pa&s. Se(reW Ger81 secretsGenal Elert Frank MlthelJn8dl c P•Jbllc Krakow12019) Paris12014} Parf$12014J cffiIIM120201 Jerusalern12017) Munith120161 0120 010117 01 .3112 22 311219 311216 010121 010118 09C816 311223 311220 311217 ActlngTrèaswer Mlgud la Rosa line120211 online120201 Jerusaem12017J Pwi$12014} 010123 311225 .3112 22 311220 311217 Con8ress cnI1 010121 010118 0115 Hurqary Onl1r20201 JerusaLYn12017) s120141 St Petersburg120131 Krtrywl2019) Murdth120161 onltr120201 010121 010118 01 OB0813 3112.23 311220 311217 311214 Chair. Pdvanced Coursescorrffllttee £tlngChlr aln KrcA thalr. Fellaw5hlps Committee Icthannes Buchner Chalr. PublIti(S Ccffirnlltee 010120 010117 "3112 22 311219 010121 311223 Emrnanol Fra8kovli thair. scire &ety CLYnmittee KTrkow120191 Munlth120161 oi(n20 010117 "3112 22 311219 Fwhan Soèln thar. Educauon CornrnRiEe (le[211} I20} Krakvat(20191 Murllth120161 SL Peter51wJrB120131 Sebille120121 Kr4kow120191 Munith12016) onlinel20201 Jffu$3lem12017) 0122 311224 010119 311221 Cedlla knlano Chthr, Wornen in sCknceWonS Grwi IWISel Chair 0120 010117 010114 110912 "3112 22 311219 311216 311213 Jerka Dumlechar. W01n$GroUp on Internon IWGII Irene Crfaz-mwno Chalr, Wortln8 Group on the Cweus of YtyJn8S(ientists Ythttcoumul Ch4Sr. Netsvork w¢ykI Gmp lyael Petht HononHYn7eMl1n0n-¥otlft9. no Director. non-Trustee rolej SeryetaryGeneral Oi¢ll20 010117 .3112 22 311219 010121 010118 311223 311220 P¢*120211 010122 311224 Jerus4em12017) 010118 seIle(lo12) 121LVJI knbjl (X¥AI 010114 oioiii oioi 311216 311213 311210
Beats Verteuy. Chalr Huryry {lIne(2020) Jr3usdem12017J is{2014) St Prtersbury120131 onlk120201 010121 010118 010115 (0813 31 IZ23 311220 311217 311214 LJrw thatr Mut•iAs Tur 010121 311224 tonlo Claz-aulntsna I12018) 010119 "3112 22 Joao laranjlnha 120181 010119 "3112 22 Mauro MrOne Krakowl20191 Krakow120191 IW120181 Onli(2020) Jwusaern12017) Muryth120161 K1ow129) P$ {X1141 P5 {20141 010120 311223 Kthstllna Maklnen nland 010120 311223 Daml¥na Rozrnan Frank Mlchel•ryll ft¥4¥JthJ Trea9Jrer tin8TreagJrer vadw Pales (ExQJftk)J SEVJetsryGerll 010119 "3112 22 1kn6tsd Klrdom 010121 OIIB CIJ 16 311223 311220 311217 Cath Rewbll¢ 0120 010117 010115 "3112 22 311219 311216 EtMJC4TION COMMirrEE Fwhan 4ln Chalr, Educatlon Cthnrnmee Committee (mline120211 FW120181 aertln120151 010122 010119 oioiis 311224 311221 311218 Manud Joao Qjsta onllne120201 010121 311224 Erkl Paulo Flnland Kraku12019) 010120 311223 Span FW120181 010119 "3112 22 Ludanevletra de Mdlo Ftw120181 010119 "3112 22 %ler Coumoul (Cowed) 010122 010120 010121 "3112 22 311221 "3112 22 Knkow IX1191 Immle Icwtedl Nlnosinoe IC¢wtEdJ 010121 .3112 22 8el Herrkn ICowe4 Th)Tr¥vtlryl Span 8erfln120151- Cwited 010116 UThllmlted Xdth Iliott (Co MTr%)tlr41 Uiutd Kidthn iknllmltsd Frank MIcherIe. fExffibJ tted Wngdorn onllne120201 jwusalem127j Munlth120161 Krakow{20191 Parfs120141 Pari$12014) 010121 010118 090916 311223 311220 311217 A¢iin8TreayJr vad P&es IExQycknJ SaJetsryGeIaI C2eth P•JblSc 010120 010117 010115 .3112 22 311219 311216 Beats Verte55y Chalr. knc Course5 fEx•offlcknJ Hun8 11120201 J¥UeM12O17) PdriS120141 st Petersbwg120131 010121 010118 010115 (BrA 31 1123 311220 311217 311214 dn8 thar. ACC Jrfka Durnie thalr, Worn Gmp on Intswthi Krakw120191 Munlch12016) 010120 010117 .3112 22 311219
FELLOWSHIPS COMMfrrEE Njaln Krd. Chalr Krakow120191 Munith12016) 010120 010117 "3112 22 311219 rIhIr Balo lkne (20201 010121 311224 ts CadI0 120181 010119 .3112 22 Valury Flonenko C112020] 010121 311224 Marfiè&Th•tres rtrfa Krakl2019) 010120 311223 Jussl Hepdokl Finland cffillne12(ml 010122 311225 Sebastlan Hiller 010121 311224 Jdants Jwa (Co-opted) KTrkry120191 F120ts1 010120 010119 311223 311219 ljmltrls ets4% 010119 "3112 22 Madej Liluwskl Anland kow120191 010120 311223 Czeth lwtll¢ Krakow120191 010120 311223 Cedric Notredame Spain 120ts1 010119 .3112 22 Ne5rfn Kartal Ozer Turkw lkne{20201 010121 311224 nte Aublo Sn Kraktt•120191 010120 311223 GrdP SUra1 FMUÈ {20) 010119 .3112 22 Ayferyaldn {CwMffll Turk 010122 010118 .3112 22 311221 Jwusern12017) onllnel20201 Jerusalem12011 Munlch120161 KTrkvw{20191 P¥ls 120141 P¥O$12014) Frank Michelan8ell fEx4ytl>J TreagJrw Adn8Trea5urer vadt4 Paees IEx-omdoJ Lknited KJrdom 010121 010118 J0916 311223 311220 311217 Cuch ubl 010120 010117 010115 .3112 22 311219 311216 FINPIC£COMMirrEE Fk MIchelaelL tha tknfted Wn8dorn cmllne12020) jerUn {20171 Munlth12016) 010121 010118 C816 311223 311220 311217 A¢UngTreagJrer Frantesco Bonoky ltr)e120201 010121 311224 Jod Sussrnan Kjakow (20191 0120 311223 vadov Pale5 IExQfflckn} etsry Gener Czeth Republk Krakow120191 Parfs120141 Pad$120141 010120 010117 010115 "3112 22 311219 311216 Johwnes thTher IErt)frlo} thalr, PuNlcatfjcffis C£¥nrnlttoe Germary online120201 010121 311223 Laszlo Fé)S IC¢wtsd) Huwry 010121 .3112 22
PUBUfATIONS COMMfryEE Jthannes Buthner. Chalr GeTh¥ (mllne {20201 010121 311223 Marc 8aumann Fknl¥ L1e(2020I 010121 311224 CongJelDGuwrl Spa {20181 010119 .3112 22 Jthannes Herrrnann Ilne12021) 010122 311225 Mardn Malka Pt4and Ilne12021} 010122 311225 Mosialos up120181 010119 .3112 22 Frar Mlthelangell fEx-Ollth) (mlkne120201 Jwusalern12017) Munlth120161 Krakow12019) Parf512014} Parts12014) oisn 010118 (8C816 311223 311220 311217 £tln8Treasurff Vadav PatÈs ILTrfftiol Clath Iwublk 010120 010117 010115 .3112 22 311219 311216 saEKEfvNDSoCIy CCAMrrrEE Errffianoull Fra¢11$, Kraku#l2019) Murlch120161 online12020) 0120 010117 .3112 22 311219 MauroTtyti 010121 311224 Mdlts Vldak(pi IIne121) Ql(ll22 311225 Enrlque 14lnbwe2 onlkne120201 010121 311224 Raffaele Porta Icwted) C(oPted{2ffllj jerusa (20171 0122 oioi 311222 311221 tsabel VarelNleto ICowtEd) 010121 010117 Munlth120161 311220 Frank Mithelanudi (ExQfrknJ United KSn8dom online120201 Jerusath12017) Munkth12016) 010121 010118 C8C816 311223 311220 311217 Vad•4 Pat• fE¥QffthJ Qeth P•U1C Kr•kow12Q191 Parls120141 P¥is12014) 010120 010117 01 .3112 22 311219 311216 Miguel la Rosa C Couhsdlor fEx-OJAkknJ linel20201 jeru511(2017) Parts12014) 010121 010118 oioiis .3112 22 311220 311217 WORKING GROUP ON CAREERS OFycWI XIENTISTS Irene Dtaz-Mc(eno. Cha 5patn Ihe120x)I Jerus8kn12017) 010121 01 311223 311220 nna J4gu4ak (Co•tedJ Pdand 0121 .3112 22 Vlasumll Kulda (Co•J C2eth pUblIC 311222 lerka [mIe ICtr(pted} 010122 311223
Frank Mlchdan8ell (Ex4)TtknJ Treasurer ActlnB Treasur United Kr¥d OnNl2020) Jeru5aem12017) Munkh {2016} 010121 010118 09(816 311223 311220 311217 vadav Patss IExofflcknl Seuetary Genera} Qeth P4ubllc 12019) P$ (2014} Pwis12014) 0120 010117 oioi .3112 22 311219 311216 WORKING GROUPON lTr[GRATION (WGII Jerka (halr Krakuw 1x1191 Munith120161 FWI20) oi(n20 010117 "3112 22 311219 Berfec srwla 010119 .3112 22 Tatiana 80rt5v4a rne FW {28) 010119 .3112 22 Frnnk Mithelanudi fE¥Qfv)I Unlted Kn8dom <ffili{20201 Juusalem1201 Munith120161 Kraku•{2019) Parls12014} P¥ls12014) onllr120211 IW120181 onllne120201 Jerusth1201 Pari$12014} St pdersbur8120131 010121 010118 (Y3 09 16 311223 311220 311217 Lttn8TreagJrw vadav Pates (Ex-offlrk)) Seuetsry General 12eth Ilewbllc 010120 010117 010115 "3112 22 311219 311216 Forhan ln fEx4JthJ thalr, Education CLYnrnKtee Turk 010122 010119 311224 311221 Beats Verte55y [£¥11 Huwy 010121 010118 oioiis cfjce 3112.23 311220 311217 311214 £Un8 Chdr. KC WORN6 GROUP ON THE FE&S NEPbVCfflK ler CM01. {JIrPeTS0n onltr120211 010122 311224 drea Belldli ue120181 oi .3112 22 AI BuTak Ozkaya Iv12021) 22 311225 La%dO NOtray (Dekgated) lex-Fell0hIp5 Commlttsel Hwyry (22 311225 Enrlquevlzuera Min8uez IDeWea) ISdu¢ce and Sodety Comrnltreel 0122 311225 BSTufk Ioelegrte {ex.Publicatbons Comrnittee) ith0 Fé5Q5 Icw)te {furnerth•lr, FE85 NetwoYkWGI 010118 311225 Hur8ary 010122 311222 Irene Claz-moreno {CtroptedJ thalr, Woykin8 on theCKews ofYnI Sdenlosts (m4nel2(1201 010121 311223 Je1[2017) 01 311220
Hurq Lmllne120201 Jerusalem12017) Pwts120141 st Petersburs P0131 010121 010118 oioiis 0813 3112.23 311220 311217 311214 alr. AAvanced CwrsesC¢¥T¥nlitee dn8cIr. AC£ WORKING GROUP ON WOMEtI IN SaEN QII Cedlrd Maria Chalr Krakow120191 Munlth120161 51 PetMsbu(8 {2013) Ile120121 ne[2020) lerusalwn {201 unlth12016) 010120 010117 010114 110912 .3112 22 311219 311216 311213 Chalr FTrnk mI(lanSl (ExQn} 010121 010118 Lvg 09 16 311223 311220 311217 £tinB Treaswer vad* Pates (E¥•k)J Seuet4ryGeneral Qeth IUblIC Krtow12019) Pwis120141 P¥is120141 010120 010117 oioi .3112 22 311219 311216
Appendix 4 - FEBS Fellowships 2022 FE8S Excell•neÈ Award Year stsrted FEA- 2022 Natiortali France German Nethedands Francè Portu Netherlands Austria Bel um FEBS Lon Term fellows Year started- 2021 Frorn Czech Re German sto German .USA USA Netherfands Bel um UK USA. Netherfands Bel iurn Germa um & s1Zerland To German United 'Th German Netherlands Swtrerland utlic dorn France Netherlands FEBS Summer Short-Term fell(wtshi From To Hun United lfj"n asn Sweden United Israel Gerrnan Netherlant United United ain Ffance FEBS Short-Term fèllowshi From Portu To Uniie¢J Sweden Bel iurn Netherfands ain German German Portu dom ain Portu Greece United TrQ"n ain German German Israel France Greece Turke dwn dom Netherlands 10 10 Sert¥a Germany Fran Slovenia United German German Sweden France SltIerland Bel um Geirnan United Kin BS Collaborabve Develo From To Serbia Oerimark Arrnenia Germa Tunisia Netherlands Armenia Frae mental 12 13 14 15 16 17 18 19 20 21 dom Turkè Sp31n Russia Isra Portu FEBS Ukranian Sh¢yl-Term Fellowshi From Tg Ukraine France Ukraine Austria Ukraint Palld Ukraine Poland Ukraine United Ukraine Poland Ukraine Germa Ukraine Bel ium Ukiaine German Ukrainè Austria dom Duration 4 months 3 monttr 3 montrs 3 rnonths 3 rnonths 4 rnonths 4 months 4 montr 4 monttK 4 months Netherland5 ain om 10
AppendSx 5- Advanced cours 2022 Tr NwMkrobKI p•1crt 31-Sep8 ¥)22 lor4£nlItI•nsPjrtOr5..1r0mm0fjtQ Jrmn. ir¢. I 5.kl 1022 Myl¥X)2D2 io Fr4r 7Idy2021 8SAd¥fftiredLethreCcAwse'4th DDn I&112022 FE8SW¢Kkshop' P(Y5.. •ttheknTert4¢ bÈrwh•ilth Prc4BtyIsT 1fy1442022 Prof 12- 10. 1022 u$. P¢Ot&n5•rétheSilnier•rliw4lnOry•dlo $rtse515FO Pffjl.Or.Érf4Th i9mty.4j1È 4ltharA dISe. ntxè& 19- 27May2022 M4trlxP•ih&ldoy.SWlfft¢4ndMc4ocL4 Tirbyts IOM•y2022 InLffe. [•thl c15e 27Sep. IOrE Veni¢eS4JmrneTSdKd2021..TrecTEtClCc1y OrOprt•V•rf Or 21-26 16-24 3&fL¥¥pXth. ffi( hJrKlrAltod15815' upJ•t• ShMDIN¢)<(On8kNA> FE85Ath4nc¢d LÈcturCtyw5etsieic4r SuifatÈS and Inrerfa¢es"Frys èt 11-17 I¥l4JwlQ22 I9.24 2022 FE85Pr4cI cours•"Mkrospecfftc&xi.' FuDclkn4llMaO181Cal 5Trsfgrn5" Jssopt Zm2 Drlr•r•D1- 2¥25Al•tth 2022 FEU5AthntedLettvreCourse 1>1S5vpt7022 Exonithehfft l[•Dxrlptornlc5•nd wclrcnielty pI.•A+thLS IlhlEn IL-L6Sept2022 erthDr¢•rye15 fw4ntt.•¢wie knttr¥wtity 36sot- iOu2022 14511n1ntèvan-pr0E4fftgr&5w1th ¢*tV¢n5.photsi5. r¢utron&ird miy¢1r p1. Nissen
I5Y2 TtytriYTF 129